<NAME id="8194_2" start="9" all_names="PRICECOMPETITION" local_name_id="1" end="26" >Price Competition</NAME>

<NAME id="8194_3" start="43" all_names="RESTORATIONACT" local_name_id="2" end="58" >Restoration Act</NAME>

<DATE start="62" end="66" id="8194_1" >1984</DATE>

<NAME id="8194_4" start="68" all_names="HATCH-WAXMANACT" local_name_id="3" end="84" >Hatch-Waxman Act</NAME>

<ORGANIZATION start="302" end="316" id="8194_5" >Administration</ORGANIZATION>

<LEGAL_ROLE start="614" local_name_id="4" name="Solvay Pharmaceuticals" end="624" id="8194_6" >Respondent</LEGAL_ROLE>

<NAME id="8194_7" start="625" all_names="SOLVAYPHARMACEUTICALS" local_name_id="4" end="647" >Solvay Pharmaceuticals</NAME>

<NAME id="8194_8" start="699" all_names="ANDROGEL" local_name_id="5" end="707" >AndroGel</NAME>

<LEGAL_ROLE plural="True" name="Actavis" id="8194_9" start="723" local_name_id="6" end="734" >respondents</LEGAL_ROLE>

<NAME id="8194_10" start="735" all_names="ACTAVIS" local_name_id="6" end="742" >Actavis</NAME>

<PERSON start="747" end="754" id="8194_11" >Paddock</PERSON>

<NAME id="8194_12" start="853" all_names="SOLVAY" local_name_id="7" end="859" >Solvay</NAME>

<NAME id="8194_13" start="923" all_names="SOLVAY" local_name_id="7" end="929" >Solvay</NAME>

<NAME id="8194_14" start="935" all_names="ACTAVIS" local_name_id="6" end="942" >Actavis</NAME>

<PERSON start="947" end="954" id="8194_15" >Paddock</PERSON>

<NAME id="8194_16" start="1045" all_names="ACTAVIS" local_name_id="6" end="1052" >Actavis</NAME>

<NAME id="8194_17" start="1115" all_names="ACTAVIS" local_name_id="6" end="1122" >Actavis</NAME>

<NAME id="8194_18" start="1182" all_names="SOLVAY" local_name_id="7" end="1188" >Solvay</NAME>

<PROFESSION start="1302" plural="True" end="1309" id="8194_19" >doctors</PROFESSION>

<NAME id="8194_20" start="1385" all_names="SOLVAY" local_name_id="7" end="1391" >Solvay</NAME>

<LEGAL_ROLE start="1400" local_name_id="8" name="Par" end="1410" id="8194_21" >respondent</LEGAL_ROLE>

<NAME id="8194_22" start="1411" all_names="PAR" local_name_id="8" end="1414" >Par</NAME>

<PERSON start="1475" end="1482" id="8194_23" >Paddock</PERSON>

<ORGANIZATION start="1489" end="1513" id="8194_27" >Federal Trade Commission</ORGANIZATION>

<LEGAL_ROLE start="1546" plural="True" end="1557" id="8194_28" >respondents</LEGAL_ROLE>

<NAME id="8194_29" start="1577" all_names="FEDERALTRADECOMMISSIONACT" local_name_id="9" end="1605" >Federal Trade Commission Act</NAME>

<NAME id="8194_30" start="1737" all_names="SOLVAY" local_name_id="7" end="1743" >Solvay</NAME>

<ORGANIZATION start="1768" end="1782" id="8194_31" >District Court</ORGANIZATION>

<CITATION lookup_key="ftc'scomplaint#1" citation_local_level_id="0" entry_type="case_key" name="FTC's complaint" id="8194_32" start="2538" id1="Dummy_File_364532" no_current_file="True" line="3" citation_global_level_id="364531.001" end="2553" >FTC's complaint</CITATION>

<NAME id="8194_33" start="2555" all_names="PP" local_name_id="10" end="2557" >Pp</NAME>

<NAME id="8194_50" start="2704" all_names="SOLVAY" local_name_id="7" end="2710" >Solvay</NAME>

<LEGAL_ROLE start="3060" end="3069" id="8194_51" >plaintiff</LEGAL_ROLE>

<LEGAL_ROLE start="3088" plural="True" end="3098" id="8194_52" >defendants</LEGAL_ROLE>

<LEGAL_ROLE start="3151" plural="True" end="3161" id="8194_53" >defendants</LEGAL_ROLE>

<LEGAL_ROLE start="3196" end="3205" id="8194_54" >plaintiff</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364533" start="3693" alternative_keys="['u.s._333_287']" line="4" party2_short="Material" end="3726" standard_reporter="U.S." citation_local_level_id="1" volume="333" party1="United States" party2="Line Material Co" id="8194_38" no_current_file="True" page_number="287" lookup_key="u.s._333_287" citation_global_level_id="364532.003" party1_short="States" >United States v. Line Material Co</CITATION>

<GPE start="3693" party1_of="8194_38" end="3706" id="8194_42" >United States</GPE>

<ORGANIZATION start="3710" party2_of="8194_38" end="3726" id="8194_43" >Line Material Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_364533" start="3729" lookup_key="u.s._333_287" standard_reporter="U.S." end="3747" page_number="287" reporter="U. S." citation_local_level_id="2" paragraph_number="310" id="8194_34" volume="333" no_current_file="True" citation_global_level_id="364532.003" >333 U. S. 287, 310</CITATION>

<ORGANIZATION start="3870" end="3875" id="8194_55" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364534" start="3995" alternative_keys="['u.s._374_174']" line="4" party2_short="Mfg" end="4026" standard_reporter="U.S." citation_local_level_id="3" volume="374" party1="United States" party2="Singer Mfg. Co" id="8194_39" no_current_file="True" page_number="174" lookup_key="u.s._374_174" citation_global_level_id="364533.003" party1_short="States" >United States v. Singer Mfg. Co</CITATION>

<GPE start="3995" party1_of="8194_39" end="4008" id="8194_44" >United States</GPE>

<ORGANIZATION start="4012" party2_of="8194_39" end="4026" id="8194_45" >Singer Mfg. Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_364534" start="4029" lookup_key="u.s._374_174" standard_reporter="U.S." end="4042" page_number="174" reporter="U. S." citation_local_level_id="4" citation_global_level_id="364533.003" volume="374" id="8194_35" no_current_file="True" >374 U. S. 174</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364535" start="4044" alternative_keys="['u.s._342_371']" line="4" party2_short="Wrinkle" end="4077" standard_reporter="U.S." citation_local_level_id="5" volume="342" party1="United States" party2="New Wrinkle, Inc" id="8194_40" no_current_file="True" page_number="371" lookup_key="u.s._342_371" citation_global_level_id="364534.003" party1_short="States" >United States v. New Wrinkle, Inc</CITATION>

<GPE start="4044" party1_of="8194_40" end="4057" id="8194_46" >United States</GPE>

<ORGANIZATION start="4061" party2_of="8194_40" end="4077" id="8194_47" >New Wrinkle, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_364535" start="4080" lookup_key="u.s._342_371" standard_reporter="U.S." end="4093" page_number="371" reporter="U. S." citation_local_level_id="6" citation_global_level_id="364534.003" volume="342" id="8194_36" no_current_file="True" >342 U. S. 371</CITATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364536" start="4095" alternative_keys="['u.s._283_163']" line="4" party2_short="States" end="4138" standard_reporter="U.S." citation_local_level_id="7" volume="283" party1="Standard Oil Co. (Indiana)" party2="United States" id="8194_41" no_current_file="True" page_number="163" lookup_key="u.s._283_163" citation_global_level_id="364535.003" party1_short="Oil" >Standard Oil Co. (Indiana) v. United States</CITATION>

<NAME id="8194_48" start="4095" all_names="STANDARDOILCO(INDIANA)" local_name_id="11" end="4121" party1_of="8194_41" >Standard Oil Co. (Indiana)</NAME>

<GPE start="4125" party2_of="8194_41" end="4138" id="8194_49" >United States</GPE>

<CITATION entry_type="standard_key" line="4" id1="Dummy_File_364536" start="4140" lookup_key="u.s._283_163" standard_reporter="U.S." end="4153" page_number="163" reporter="U. S." citation_local_level_id="8" citation_global_level_id="364535.003" volume="283" id="8194_37" no_current_file="True" >283 U. S. 163</CITATION>

<NAME id="8194_56" start="4168" all_names="HATCH-WAXMANACT" local_name_id="3" end="4184" >Hatch-Waxman Act</NAME>

<PROFESSION start="4187" end="4194" id="8194_57" >general</PROFESSION>

<NAME id="8194_58" start="4427" all_names="PP" local_name_id="10" end="4429" >Pp</NAME>

<PROFESSION start="4506" end="4513" id="8194_75" >general</PROFESSION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_325575" start="5152" alternative_keys="['u.s._476_447']" line="5" party2_short="Federation" end="5189" citation_local_level_id="9" party1="FTC" party2="Indiana Federation of Dentists" id="8194_72" citation_global_level_id="325574.004" party1_short="FTC" >FTC v. Indiana Federation of Dentists</CITATION>

<ORGANIZATION start="5152" party1_of="8194_72" end="5155" id="8194_73" >FTC</ORGANIZATION>

<ORGANIZATION start="5159" party2_of="8194_72" end="5189" id="8194_74" >Indiana Federation of Dentists</ORGANIZATION>

<ORGANIZATION start="5159" end="5177" id="8194_76" >Indiana Federation</ORGANIZATION>

<CITATION entry_type="standard_key" line="5" id1="Dummy_File_325575" start="5191" lookup_key="u.s._476_447" standard_reporter="U.S." end="5213" page_number="447" reporter="U. S." citation_local_level_id="10" paragraph_number="460-461" id="8194_71" volume="476" no_current_file="True" citation_global_level_id="325574.001" >476 U. S. 447, 460-461</CITATION>

<NAME id="8194_77" start="5388" all_names="HATCH-WAXMANACT" local_name_id="3" end="5404" >Hatch-Waxman Act</NAME>

<NAME id="8194_78" start="7213" all_names="PP" local_name_id="10" end="7215" >Pp</NAME>

<ORGANIZATION start="7234" end="7239" id="8194_86" >Court</ORGANIZATION>

<ORGANIZATION start="7328" plural="True" end="7334" id="8194_87" >Courts</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345279" start="7457" alternative_keys="['u.s._526_756']" line="6" party2_short="FTC" end="7487" citation_local_level_id="11" party1="California Dental Assn." party2="FTC" id="8194_83" citation_global_level_id="345278.004" party1_short="Dental" >California Dental Assn. v. FTC</CITATION>

<ORGANIZATION start="7457" party1_of="8194_83" end="7480" id="8194_84" >California Dental Assn.</ORGANIZATION>

<ORGANIZATION start="7484" party2_of="8194_83" end="7487" id="8194_85" >FTC</ORGANIZATION>

<CITATION entry_type="standard_key" line="6" id1="Dummy_File_345279" start="7489" alternative_keys="['dentalftc#1']" lookup_key="u.s._526_756" standard_reporter="U.S." end="7507" page_number="756" reporter="U. S." citation_local_level_id="12" paragraph_number="775" id="8194_82" volume="526" no_current_file="True" citation_global_level_id="345278.003" >526 U. S. 756, 775</CITATION>

<NAME id="8194_88" start="7516" all_names="PP" local_name_id="10" end="7518" >Pp</NAME>

<CITATION entry_type="standard_key" line="7" id1="Dummy_File_364537" start="7527" lookup_key="f.3d_677_1298" standard_reporter="F.3D" end="7541" page_number="1298" reporter="F. 3d" citation_local_level_id="13" citation_global_level_id="364536.001" id="8194_92" volume="677" no_current_file="True" >677 F. 3d 1298</CITATION>

<PERSON start="7567" end="7573" id="8194_93" >Breyer</PERSON>

<ORGANIZATION start="7608" end="7613" id="8194_94" >Court</ORGANIZATION>

<PERSON start="7624" end="7631" id="8194_95" >Kennedy</PERSON>

<PERSON start="7633" end="7641" id="8194_96" >Ginsburg</PERSON>

<PERSON start="7643" end="7652" id="8194_97" >Sotomayor</PERSON>

<NAME id="8194_98" start="7658" all_names="KAGANJJ" local_name_id="12" end="7667" >Kagan, JJ</NAME>

<PERSON start="7678" end="7685" id="8194_99" >Roberts</PERSON>

<PERSON start="7731" end="7737" id="8194_100" >Scalia</PERSON>

<PERSON start="7742" plural="True" end="7752" id="8194_101" >Thomas, JJ</PERSON>

<NAME id="8194_102" start="7763" all_names="ALITO" local_name_id="13" end="7768" >Alito</NAME>

<ORGANIZATION start="7848" end="7853" id="8194_103" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="9" page_number="____" start="7855" lookup_key="u.s._570_____" standard_reporter="U.S." end="7876" year="2013" reporter="U. S." citation_local_level_id="14" citation_global_level_id="364507.001" id="8194_104" id1="Dummy_File_364508" volume="570" no_current_file="True" >570 U. S. ____ (2013)</CITATION>

<DATE start="7871" citation_local_level_id="14" citation_global_level_id="364507.001" end="7875" id="8194_105" >2013</DATE>

<NAME id="8194_108" start="7877" all_names="NOTICE" local_name_id="14" end="7883" >NOTICE</NAME>

<NAME id="8194_109" start="7986" all_names="STATESREPORTS" local_name_id="15" end="8000" >States Reports</NAME>

<PROFESSION start="8038" end="8046" id="8194_110" >Reporter</PROFESSION>

<ORGANIZATION start="8061" end="8074" id="8194_111" >Supreme Court</ORGANIZATION>

<NAME id="8194_112" start="8089" all_names="STATES" local_name_id="16" end="8095" >States</NAME>

<GPE start="8097" end="8107" id="8194_113" >Washington</GPE>

<DATE start="8115" end="8119" id="8194_107" >2054</DATE>

<DOCKET start="8253" entry_type="docket" line="11" end="8259" id="8194_114" >12-416</DOCKET>

<CITATION entry_type="party_key" line="12" id1="Dummy_File_364538" start="8260" lookup_key="commissionactavis#1" party2_short="ACTAVIS" end="8320" citation_local_level_id="15" party1="FEDERAL TRADE COMMISSION," party2="ACTAVIS, INC., et al" id="8194_115" no_current_file="True" party1_role="petitioner" citation_global_level_id="364537.001" party1_short="COMMISSION" >FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al</CITATION>

<NAME id="8194_116" start="8260" all_names="FEDERALTRADECOMMISSION" local_name_id="17" end="8285" party1_of="8194_115" >FEDERAL TRADE COMMISSION,</NAME>

<ORGANIZATION start="8260" end="8284" id="8194_119" >FEDERAL TRADE COMMISSION</ORGANIZATION>

<LEGAL_ROLE start="8286" end="8296" id="8194_118" >PETITIONER</LEGAL_ROLE>

<GPE start="8300" party2_of="8194_115" end="8320" id="8194_117" >ACTAVIS, INC., et al</GPE>

<ORGANIZATION start="8300" end="8312" id="8194_120" >ACTAVIS, INC</ORGANIZATION>

<DATE start="8408" end="8421" id="8194_124" >June 17, 2013</DATE>

<PROFESSION start="8424" document_level_name_id="18" party="BREYER" end="8431" id="8194_125" >Justice</PROFESSION>

<PERSON start="8432" end="8438" id="8194_126" >Breyer</PERSON>

<ORGANIZATION start="8468" end="8473" id="8194_127" >Court</ORGANIZATION>

<ORGANIZATION start="8476" end="8483" id="8194_135" >Company</ORGANIZATION>

<ORGANIZATION start="8491" end="8498" id="8194_136" >Company</ORGANIZATION>

<ORGANIZATION start="8580" end="8587" id="8194_137" >Company</ORGANIZATION>

<ORGANIZATION start="8692" end="8699" id="8194_138" >Company</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_323684" start="9190" alternative_keys="['u.s._498_46']" line="16" party2_short="BRG" end="9215" citation_local_level_id="16" party1="Palmer" party2="BRG of Ga., Inc" id="8194_131" citation_global_level_id="323683.005" party1_short="Palmer" >Palmer v. BRG of Ga., Inc</CITATION>

<PERSON start="9190" party1_of="8194_131" end="9196" id="8194_132" >Palmer</PERSON>

<ORGANIZATION start="9200" party2_of="8194_131" end="9215" id="8194_133" >BRG of Ga., Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="16" id1="Dummy_File_323684" start="9218" lookup_key="u.s._498_46" standard_reporter="U.S." end="9230" page_number="46" reporter="U. S." citation_local_level_id="17" citation_global_level_id="323683.001" id="8194_130" volume="498" no_current_file="True" >498 U. S. 46</CITATION>

<DATE start="9232" citation_local_level_id="17" citation_global_level_id="323683.001" end="9236" id="8194_134" >1990</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<ORGANIZATION start="9340" end="9364" id="8194_148" >Federal Trade Commission</ORGANIZATION>

<CITATION entry_type="party_key" line="17" id1="Dummy_File_364537" start="9700" alternative_keys="['f.3d_677_1298']" lookup_key="ftcpharmaceuticals#1" party2_short="Pharmaceuticals" end="9734" citation_local_level_id="18" party1="FTC" party2="Watson Pharmaceuticals, Inc" id="8194_144" citation_global_level_id="364536.002" party1_short="FTC" >FTC v. Watson Pharmaceuticals, Inc</CITATION>

<ORGANIZATION start="9700" party1_of="8194_144" end="9703" id="8194_145" >FTC</ORGANIZATION>

<ORGANIZATION start="9707" party2_of="8194_144" end="9734" id="8194_146" >Watson Pharmaceuticals, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="1298" start="9737" alternative_keys="['ftcpharmaceuticals#1']" line="17" standard_reporter="F.3D" end="9764" year="2012" lookup_key="f.3d_677_1298" reporter="F. 3d" citation_local_level_id="19" paragraph_number="1312" id="8194_143" id1="Dummy_File_364537" volume="677" no_current_file="True" citation_global_level_id="364536.001" >677 F. 3d 1298, 1312 (2012)</CITATION>

<DATE start="9759" citation_local_level_id="19" citation_global_level_id="364536.001" end="9763" id="8194_147" >2012</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<LEGAL_ROLE start="10594" end="10604" id="8194_157" >Petitioner</LEGAL_ROLE>

<NAME id="8194_158" start="10648" all_names="LAW" local_name_id="18" end="10651" >Law</NAME>

<DATE start="10653" end="10657" id="8194_153" >2046</DATE>

<DATE start="10674" end="10678" id="8194_154" >2012</DATE>

<NAME id="8194_159" start="10693" all_names="AREEDA" local_name_id="19" end="10699" >Areeda</NAME>

<NAME id="8194_160" start="10702" all_names="HOVENKAMP" local_name_id="20" end="10711" >Hovenkamp</NAME>

<NAME id="8194_161" start="10713" all_names="SENSIBLEANTITRUSTRULES" local_name_id="21" end="10737" >Sensible Antitrust Rules</NAME>

<NAME id="8194_162" start="10742" all_names="PHARMACEUTICALCOMPETITION" local_name_id="22" end="10768" >Pharmaceutical Competition</NAME>

<DATE start="10798" end="10802" id="8194_155" >2004</DATE>

<NAME id="8194_163" start="10914" all_names="PRICECOMPETITION" local_name_id="1" end="10931" >Price Competition</NAME>

<NAME id="8194_164" start="10948" all_names="RESTORATIONACT" local_name_id="2" end="10963" >Restoration Act</NAME>

<DATE start="10967" end="10971" id="8194_156" >1984</DATE>

<NAME id="8194_165" start="10976" all_names="STAT" local_name_id="23" end="10980" >Stat</NAME>

<NAME id="8194_166" start="11034" all_names="HATCH-WAXMANACT" local_name_id="3" end="11050" >Hatch-Waxman Act</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_167" start="11138" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="11158" >New Drug Application</NAME>

<ORGANIZATION start="11188" end="11202" id="8194_168" >Administration</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_179" start="11801" all_names="HATCH-WAXMANACT" local_name_id="3" end="11817" >Hatch-Waxman Act</NAME>

<NAME id="8194_180" start="11872" all_names="NEWDRUGAPPLI-CATION" local_name_id="25" end="11893" >New Drug Appli-cation</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_362645" start="12036" alternative_keys="['u.s._566____']" line="22" party2_short="S" end="12096" citation_local_level_id="20" party1="Caraco Pharmaceutical Laboratories, Ltd." party2="Novo Nordisk A/S" id="8194_171" citation_global_level_id="362644.017" party1_short="Laboratories" >Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S</CITATION>

<ORGANIZATION start="12036" party1_of="8194_171" end="12076" id="8194_173" >Caraco Pharmaceutical Laboratories, Ltd.</ORGANIZATION>

<ORGANIZATION start="12036" end="12075" id="8194_181" >Caraco Pharmaceutical Laboratories, Ltd</ORGANIZATION>

<ORGANIZATION start="12080" party2_of="8194_171" end="12096" id="8194_174" >Novo Nordisk A/S</ORGANIZATION>

<CITATION entry_type="standard_key" line="22" id1="Dummy_File_362645" start="12098" lookup_key="u.s._566____" standard_reporter="U.S." end="12111" page_number="___" reporter="U. S." citation_local_level_id="21" citation_global_level_id="362644.003" id="8194_169" volume="566" no_current_file="True" >566 U. S. ___</CITATION>

<DATE start="12118" end="12122" id="8194_177" >2012</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_343614" start="12352" alternative_keys="['u.s._496_661']" line="22" party2_short="Medtronic" end="12385" citation_local_level_id="22" party1="Eli Lilly &amp; Co." party2="Medtronic, Inc" id="8194_172" citation_global_level_id="343613.007" party1_short="Lilly" >Eli Lilly &amp; Co. v. Medtronic, Inc</CITATION>

<ORGANIZATION start="12352" party1_of="8194_172" end="12367" id="8194_175" >Eli Lilly &amp; Co.</ORGANIZATION>

<ORGANIZATION start="12352" end="12366" id="8194_182" >Eli Lilly &amp; Co</ORGANIZATION>

<ORGANIZATION start="12371" party2_of="8194_172" end="12385" id="8194_176" >Medtronic, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="661" start="12388" alternative_keys="['lillymedtronic#1']" line="22" standard_reporter="U.S." end="12413" year="1990" lookup_key="u.s._496_661" reporter="U. S." citation_local_level_id="23" paragraph_number="676" id="8194_170" id1="Dummy_File_343614" volume="496" no_current_file="True" citation_global_level_id="343613.003" >496 U. S. 661, 676 (1990)</CITATION>

<DATE start="12408" citation_local_level_id="23" citation_global_level_id="343613.003" end="12412" id="8194_178" >1990</DATE>

<NAME id="8194_183" start="12419" all_names="HATCH-WAXMAN" local_name_id="26" end="12431" >Hatch-Waxman</NAME>

<NAME id="8194_184" start="12579" all_names="CARACO" local_name_id="27" end="12585" >Caraco</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_192" start="12668" all_names="HATCH-WAXMANACT" local_name_id="3" end="12684" >Hatch-Waxman Act</NAME>

<NAME id="8194_193" start="12837" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="12857" >New Drug Application</NAME>

<NAME id="8194_194" start="13007" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="13027" >New Drug Application</NAME>

<NAME id="8194_195" start="13115" all_names="CARACO" local_name_id="27" end="13121" >Caraco</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_197" start="13642" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="13662" >New Drug Application</NAME>

<PROFESSION start="13774" plural="True" end="13780" id="8194_198" >counts</PROFESSION>

<DATE start="13836" end="13840" id="8194_196" >2006</DATE>

<NAME id="8194_199" start="13846" all_names="SUPP" local_name_id="28" end="13850" >Supp</NAME>

<NAME id="8194_200" start="13896" all_names="CARACO" local_name_id="27" end="13902" >Caraco</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_203" start="14379" all_names="HATCH-WAXMAN" local_name_id="26" end="14391" >Hatch-Waxman</NAME>

<NAME id="8194_204" start="14474" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="14494" >New Drug Application</NAME>

<LEGAL_ROLE start="14531" end="14540" id="8194_205" >applicant</LEGAL_ROLE>

<PERSON start="14998" end="15006" id="8194_206" >Hemphill</PERSON>

<NAME id="8194_207" start="15019" all_names="DELAY" local_name_id="29" end="15024" >Delay</NAME>

<NAME id="8194_208" start="15026" all_names="PHARMACEUTICALPATENTSETTLEMENT" local_name_id="30" end="15058" >Pharmaceutical Patent Settlement</NAME>

<NAME id="8194_209" start="15064" all_names="REGULATORYDESIGNPROBLEM" local_name_id="31" end="15089" >Regulatory Design Problem</NAME>

<DATE start="15123" end="15127" id="8194_201" >2006</DATE>

<ORGANIZATION start="15142" end="15176" id="8194_210" >Generic Pharmaceutical Association</ORGANIZATION>

<DATE start="15185" end="15189" id="8194_202" >2006</DATE>

<LEGAL_ROLE start="15333" end="15343" id="8194_211" >Petitioner</LEGAL_ROLE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<DATE start="15618" end="15622" id="8194_213" >1999</DATE>

<NAME id="8194_216" start="15624" all_names="SOLVAYPHARMACEUTICALS" local_name_id="4" end="15646" >Solvay Pharmaceuticals</NAME>

<LEGAL_ROLE start="15650" end="15660" id="8194_217" >respondent</LEGAL_ROLE>

<NAME id="8194_218" start="15675" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="15695" >New Drug Application</NAME>

<NAME id="8194_219" start="15725" all_names="ANDROGEL" local_name_id="5" end="15733" >AndroGel</NAME>

<DATE start="15771" end="15775" id="8194_214" >2000</DATE>

<DATE start="15780" end="15784" id="8194_215" >2003</DATE>

<NAME id="8194_220" start="15786" all_names="SOLVAY" local_name_id="7" end="15792" >Solvay</NAME>

<CITATION entry_type="standard_key" line="28" id1="Dummy_File_364539" start="15856" lookup_key="f.3d_677_1308" standard_reporter="F.3D" end="15874" page_number="1308" reporter="F. 3d" citation_local_level_id="24" citation_global_level_id="364538.001" id="8194_212" volume="677" no_current_file="True" >677 F. 3d, at 1308</CITATION>

<NAME id="8194_221" start="15879" all_names="HATCH-WAXMAN" local_name_id="26" end="15891" >Hatch-Waxman</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<LEGAL_ROLE start="16034" end="16044" id="8194_222" >respondent</LEGAL_ROLE>

<ORGANIZATION start="16046" end="16058" id="8194_223" >Actavis, Inc</ORGANIZATION>

<NAME id="8194_224" start="16075" all_names="WATSONPHARMACEUTICALS" local_name_id="32" end="16097" >Watson Pharmaceuticals</NAME>

<NAME id="8194_225" start="16121" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="16141" >New Drug Application</NAME>

<NAME id="8194_226" start="16175" all_names="ANDROGEL" local_name_id="5" end="16183" >AndroGel</NAME>

<ORGANIZATION start="16199" plural="True" end="16219" id="8194_227" >Paddock Laboratories</ORGANIZATION>

<LEGAL_ROLE start="16228" end="16238" id="8194_228" >respondent</LEGAL_ROLE>

<NAME id="8194_229" start="16272" all_names="NEWDRUGAPPLICATION" local_name_id="24" end="16292" >New Drug Application</NAME>

<NAME id="8194_230" start="16327" all_names="ACTAVIS" local_name_id="6" end="16334" >Actavis</NAME>

<PERSON start="16339" end="16346" id="8194_231" >Paddock</PERSON>

<NAME id="8194_232" start="16381" all_names="SOLVAY" local_name_id="7" end="16387" >Solvay</NAME>

<NAME id="8194_233" start="16476" all_names="PARPHARMACEUTICAL" local_name_id="33" end="16494" >Par Pharmaceutical</NAME>

<LEGAL_ROLE start="16507" end="16517" id="8194_234" >respondent</LEGAL_ROLE>

<PERSON start="16581" end="16588" id="8194_235" >Paddock</PERSON>

<PERSON start="16672" end="16679" id="8194_236" >Paddock</PERSON>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<NAME id="8194_240" start="16721" all_names="SOLVAY" local_name_id="7" end="16727" >Solvay</NAME>

<NAME id="8194_241" start="16777" all_names="ACTAVIS" local_name_id="6" end="16784" >Actavis</NAME>

<PERSON start="16789" end="16796" id="8194_242" >Paddock</PERSON>

<NAME id="8194_243" start="16835" all_names="ACTAVIS" local_name_id="6" end="16842" >Actavis</NAME>

<DATE start="16883" end="16887" id="8194_237" >2006</DATE>

<NAME id="8194_244" start="16966" all_names="ACTAVIS" local_name_id="6" end="16973" >Actavis</NAME>

<DATE start="17033" end="17048" id="8194_238" >August 31, 2015</DATE>

<NAME id="8194_245" start="17067" all_names="SOLVAY" local_name_id="7" end="17073" >Solvay</NAME>

<NAME id="8194_246" start="17140" all_names="ACTAVIS" local_name_id="6" end="17147" >Actavis</NAME>

<NAME id="8194_247" start="17262" all_names="SOLVAY" local_name_id="7" end="17268" >Solvay</NAME>

<PERSON start="17344" end="17351" id="8194_248" >Paddock</PERSON>

<NAME id="8194_249" start="17444" all_names="ACTAVIS" local_name_id="6" end="17451" >Actavis</NAME>

<PERSON start="17457" end="17460" id="8194_250" >App</PERSON>

<DATE start="17793" end="17797" id="8194_239" >2015</DATE>

<NAME id="8194_251" start="17818" all_names="COMPLAINT" local_name_id="34" end="17827" >Complaint</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<DATE start="17843" end="17859" id="8194_258" >January 29, 2009</DATE>

<NAME id="8194_263" start="17930" all_names="SOLVAY" local_name_id="7" end="17936" >Solvay</NAME>

<NAME id="8194_264" start="17938" all_names="ACTAVIS" local_name_id="6" end="17945" >Actavis</NAME>

<PERSON start="17947" end="17954" id="8194_265" >Paddock</PERSON>

<NAME id="8194_266" start="17960" all_names="PAR" local_name_id="8" end="17963" >Par</NAME>

<LEGAL_ROLE start="18017" plural="True" end="18028" id="8194_267" >respondents</LEGAL_ROLE>

<NAME id="8194_268" start="18048" all_names="FEDERALTRADECOMMISSIONACT" local_name_id="9" end="18076" >Federal Trade Commission Act</NAME>

<NAME id="8194_269" start="18131" all_names="SOLVAY" local_name_id="7" end="18137" >Solvay</NAME>

<PERSON start="18292" end="18295" id="8194_270" >App</PERSON>

<NAME id="8194_271" start="18301" all_names="COMPLAINT¶5SEE" local_name_id="35" end="18318" >Complaint ¶5. See</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_325575" start="18329" alternative_keys="['u.s._476_447']" line="32" party2_short="Federation" end="18366" citation_local_level_id="25" party1="FTC" party2="Indiana Federation of Dentists" id="8194_255" citation_global_level_id="325574.005" party1_short="FTC" >FTC v. Indiana Federation of Dentists</CITATION>

<ORGANIZATION start="18329" party1_of="8194_255" end="18332" id="8194_256" >FTC</ORGANIZATION>

<ORGANIZATION start="18336" party2_of="8194_255" end="18366" id="8194_257" >Indiana Federation of Dentists</ORGANIZATION>

<ORGANIZATION start="18336" end="18354" id="8194_272" >Indiana Federation</ORGANIZATION>

<CITATION entry_type="standard_key" line="32" id1="Dummy_File_325575" start="18368" lookup_key="u.s._476_447" standard_reporter="U.S." end="18386" page_number="447" reporter="U. S." citation_local_level_id="26" paragraph_number="454" id="8194_253" volume="476" no_current_file="True" citation_global_level_id="325574.001" >476 U. S. 447, 454</CITATION>

<DATE start="18388" citation_local_level_id="26" citation_global_level_id="325574.001" end="18392" id="8194_259" >1986</DATE>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<NAME id="8194_273" start="18451" all_names="SHERMANACT" local_name_id="36" end="18462" >Sherman Act</NAME>

<ORGANIZATION start="18499" end="18513" id="8194_274" >District Court</ORGANIZATION>

<CITATION lookup_key="inreandrogelantitrustlitigation#1" citation_local_level_id="27" entry_type="case_key" name="In re Androgel Antitrust Litigation" id="8194_261" start="18588" id1="Dummy_File_364540" no_current_file="True" line="32" citation_global_level_id="364539.001" end="18623" >In re Androgel Antitrust Litigation</CITATION>

<CITATION entry_type="standard_key" line="32" id1="Dummy_File_364541" start="18634" lookup_key="f.supp.2d_687_1371" standard_reporter="F.SUPP.2D" end="18660" page_number="1371" reporter="F. Supp. 2d" citation_local_level_id="28" paragraph_number="1379" id="8194_254" volume="687" no_current_file="True" citation_global_level_id="364540.001" >687 F. Supp. 2d 1371, 1379</CITATION>

<GPE start="18662" end="18667" id="8194_275" >ND Ga</GPE>

<DATE start="18669" end="18673" id="8194_260" >2010</DATE>

<CITATION lookup_key="ftc'scomplaint#2" citation_local_level_id="29" entry_type="case_key" name="FTC's complaint" id="8194_262" start="18705" id1="Dummy_File_364542" no_current_file="True" line="32" citation_global_level_id="364541.001" end="18720" >FTC's complaint</CITATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<ORGANIZATION start="18745" end="18750" id="8194_288" >Court</ORGANIZATION>

<ORGANIZATION start="18800" end="18814" id="8194_289" >District Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364543" start="19056" lookup_key="f.3d_677_1312" standard_reporter="F.3D" end="19074" page_number="1312" reporter="F. 3d" citation_local_level_id="30" citation_global_level_id="364542.001" id="8194_280" volume="677" no_current_file="True" >677 F. 3d, at 1312</CITATION>

<CITATION entry_type="party_key" line="33" id1="Dummy_File_364544" start="19241" alternative_keys="['f.3d_344_1294']" lookup_key="drugpharmaceuticals#1" party2_short="Pharmaceuticals" end="19287" standard_reporter="F.3D" citation_local_level_id="31" volume="344" party1="Valley Drug Co." party2="Geneva Pharmaceuticals, Inc" id="8194_284" no_current_file="True" page_number="1294" citation_global_level_id="364543.003" party1_short="Drug" >Valley Drug Co. v. Geneva Pharmaceuticals, Inc</CITATION>

<ORGANIZATION start="19241" party1_of="8194_284" end="19256" id="8194_285" >Valley Drug Co.</ORGANIZATION>

<ORGANIZATION start="19241" end="19255" id="8194_290" >Valley Drug Co</ORGANIZATION>

<ORGANIZATION start="19260" party2_of="8194_284" end="19287" id="8194_286" >Geneva Pharmaceuticals, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364544" start="19290" alternative_keys="['drugpharmaceuticals#1']" lookup_key="f.3d_344_1294" standard_reporter="F.3D" end="19310" page_number="1294" reporter="F. 3d" citation_local_level_id="32" paragraph_number="1304" id="8194_281" volume="344" no_current_file="True" citation_global_level_id="364543.003" >344 F. 3d 1294, 1304</CITATION>

<GPE start="19312" end="19314" id="8194_291" >CA</GPE>

<DATE start="19317" end="19321" id="8194_287" >2003</DATE>

<PERSON start="19334" end="19340" id="8194_292" >Palmer</PERSON>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364545" start="19342" lookup_key="u.s._498_50" standard_reporter="U.S." end="19358" page_number="50" reporter="U. S." citation_local_level_id="33" citation_global_level_id="364544.001" id="8194_282" volume="498" no_current_file="True" >498 U. S., at 50</CITATION>

<CITATION entry_type="standard_key" line="33" id1="Dummy_File_364546" start="19574" lookup_key="f.3d_677_1307" standard_reporter="F.3D" end="19592" page_number="1307" reporter="F. 3d" citation_local_level_id="34" citation_global_level_id="364545.001" id="8194_283" volume="677" no_current_file="True" >677 F. 3d, at 1307</CITATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<CITATION lookup_key="ftc'spetition#2" citation_local_level_id="35" entry_type="case_key" name="FTC's petition" id="8194_305" start="20429" id1="Dummy_File_364547" no_current_file="True" line="34" citation_global_level_id="364546.001" end="20443" >FTC's petition</CITATION>

<CITATION entry_type="case_key" line="34" id1="Dummy_File_364548" start="20542" alternative_keys="['f.3d_544_1323']" lookup_key="inreciprofloxacinhydrochlorideantitrustlitigation#1" standard_reporter="F.3D" end="20596" page_number="1323" volume="544" citation_local_level_id="36" citation_global_level_id="364547.003" name="In re Ciprofloxacin Hydrochloride Antitrust Litigation" id="8194_306" no_current_file="True" >In re Ciprofloxacin Hydrochloride Antitrust Litigation</CITATION>

<CITATION entry_type="standard_key" line="34" id1="Dummy_File_364548" start="20598" alternative_keys="['inreciprofloxacinhydrochlorideantitrustlitigation#1']" lookup_key="f.3d_544_1323" standard_reporter="F.3D" end="20623" page_number="1323" reporter="F. 3d" citation_local_level_id="37" paragraph_number="1332-1337" name="In re Ciprofloxacin Hydrochloride Antitrust Litigation" id="8194_299" volume="544" no_current_file="True" citation_global_level_id="364547.003" >544 F. 3d 1323, 1332-1337</CITATION>

<NAME id="8194_309" start="20625" all_names="CAFED" local_name_id="37" end="20631" >CA Fed</NAME>

<DATE start="20633" end="20637" id="8194_302" >2008</DATE>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<CITATION entry_type="case_key" line="34" id1="Dummy_File_364549" start="20650" alternative_keys="['f.3d_466_187']" lookup_key="inretamoxifencitrateantitrustlitigation#1" standard_reporter="F.3D" end="20694" page_number="187" volume="466" citation_local_level_id="38" citation_global_level_id="364548.003" name="In re Tamoxifen Citrate Antitrust Litigation" id="8194_307" no_current_file="True" >In re Tamoxifen Citrate Antitrust Litigation</CITATION>

<CITATION entry_type="standard_key" line="34" id1="Dummy_File_364549" start="20696" alternative_keys="['inretamoxifencitrateantitrustlitigation#1']" lookup_key="f.3d_466_187" standard_reporter="F.3D" end="20718" page_number="187" reporter="F. 3d" citation_local_level_id="39" paragraph_number="212-213" name="In re Tamoxifen Citrate Antitrust Litigation" id="8194_300" volume="466" no_current_file="True" citation_global_level_id="364548.003" >466 F. 3d 187, 212-213</CITATION>

<GPE start="20720" end="20722" id="8194_310" >CA</GPE>

<DATE start="20724" end="20728" id="8194_303" >2006</DATE>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<CITATION entry_type="case_key" line="34" id1="Dummy_File_364550" start="20746" alternative_keys="['f.3d_686_197']" lookup_key="inrek-durantitrustlitigation#1" standard_reporter="F.3D" end="20778" page_number="197" volume="686" citation_local_level_id="40" citation_global_level_id="364549.003" name="In re K-Dur Antitrust Litigation" id="8194_308" no_current_file="True" >In re K-Dur Antitrust Litigation</CITATION>

<CITATION entry_type="standard_key" line="34" id1="Dummy_File_364550" start="20780" alternative_keys="['inrek-durantitrustlitigation#1']" lookup_key="f.3d_686_197" standard_reporter="F.3D" end="20802" page_number="197" reporter="F. 3d" citation_local_level_id="41" paragraph_number="214-218" name="In re K-Dur Antitrust Litigation" id="8194_301" volume="686" no_current_file="True" citation_global_level_id="364549.003" >686 F. 3d 197, 214-218</CITATION>

<GPE start="20804" end="20806" id="8194_311" >CA</GPE>

<DATE start="20808" end="20812" id="8194_304" >2012</DATE>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<NAME id="8194_316" start="20858" all_names="SOLVAY" local_name_id="7" end="20864" >Solvay</NAME>

<CITATION entry_type="standard_key" line="37" id1="Dummy_File_364543" start="21217" lookup_key="f.3d_677_1312" standard_reporter="F.3D" end="21235" page_number="1312" reporter="F. 3d" citation_local_level_id="42" citation_global_level_id="364542.001" id="8194_315" volume="677" no_current_file="True" >677 F. 3d, at 1312</CITATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364533" start="21671" alternative_keys="['u.s._333_287']" line="38" party2_short="Material" end="21704" citation_local_level_id="43" party1="United States" party2="Line Material Co" id="8194_319" citation_global_level_id="364532.004" party1_short="States" >United States v. Line Material Co</CITATION>

<GPE start="21671" party1_of="8194_319" end="21684" id="8194_320" >United States</GPE>

<ORGANIZATION start="21688" party2_of="8194_319" end="21704" id="8194_321" >Line Material Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="38" id1="Dummy_File_364533" start="21707" lookup_key="u.s._333_287" standard_reporter="U.S." end="21725" page_number="287" reporter="U. S." citation_local_level_id="44" paragraph_number="308" id="8194_318" volume="333" no_current_file="True" citation_global_level_id="364532.003" >333 U. S. 287, 308</CITATION>

<DATE start="21727" citation_local_level_id="44" citation_global_level_id="364532.003" end="21731" id="8194_322" >1948</DATE>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<LEGAL_ROLE start="22231" end="22240" id="8194_323" >plaintiff</LEGAL_ROLE>

<LEGAL_ROLE start="22259" plural="True" end="22269" id="8194_324" >defendants</LEGAL_ROLE>

<LEGAL_ROLE start="22338" plural="True" end="22348" id="8194_325" >defendants</LEGAL_ROLE>

<LEGAL_ROLE start="22381" end="22390" id="8194_326" >plaintiff</LEGAL_ROLE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<CITATION entry_type="standard_key" line="39" id1="Dummy_File_364551" start="23071" lookup_key="f.3d_677_1309" standard_reporter="F.3D" end="23089" page_number="1309" reporter="F. 3d" citation_local_level_id="45" citation_global_level_id="364550.001" id="8194_331" volume="677" no_current_file="True" >677 F. 3d, at 1309</CITATION>

<ORGANIZATION start="23102" end="23107" id="8194_332" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<ORGANIZATION start="23310" end="23315" id="8194_346" >Court</ORGANIZATION>

<NAME id="8194_347" start="23319" all_names="LINEMATERIAL" local_name_id="38" end="23332" >Line Material</NAME>

<NAME id="8194_348" start="23620" all_names="SHERMANACT" local_name_id="36" end="23631" >Sherman Act</NAME>

<CITATION entry_type="standard_key" line="40" id1="Dummy_File_364552" start="23634" lookup_key="u.s._333_310" standard_reporter="U.S." end="23651" page_number="310" reporter="U. S." citation_local_level_id="46" citation_global_level_id="364551.001" id="8194_335" volume="333" no_current_file="True" >333 U. S., at 310</CITATION>

<ORGANIZATION start="23681" end="23686" id="8194_349" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_326180" start="23979" alternative_keys="['u.s._333_364']" line="40" party2_short="Gypsum" end="24019" citation_local_level_id="47" party1="United States" party2="United States Gypsum Co" id="8194_338" citation_global_level_id="326179.007" party1_short="States" >United States v. United States Gypsum Co</CITATION>

<GPE start="23979" party1_of="8194_338" end="23992" id="8194_340" >United States</GPE>

<ORGANIZATION start="23996" party2_of="8194_338" end="24019" id="8194_341" >United States Gypsum Co</ORGANIZATION>

<ORGANIZATION start="24003" end="24019" id="8194_350" >States Gypsum Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="40" id1="Dummy_File_326180" start="24022" lookup_key="u.s._333_364" standard_reporter="U.S." end="24044" page_number="364" reporter="U. S." citation_local_level_id="48" paragraph_number="390-391" id="8194_336" volume="333" no_current_file="True" citation_global_level_id="326179.001" >333 U. S. 364, 390-391</CITATION>

<DATE start="24046" citation_local_level_id="48" citation_global_level_id="326179.001" end="24050" id="8194_344" >1948</DATE>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<NAME id="8194_351" start="24183" all_names="SHERMANACT" local_name_id="36" end="24194" >Sherman Act</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345075" start="24246" alternative_keys="['u.s._382_172']" line="40" party2_short="Chemical" end="24310" citation_local_level_id="49" party1="Walker Process Equipment, Inc." party2="Food Machinery &amp; Chemical Corp" id="8194_339" citation_global_level_id="345074.004" party1_short="Equipment" >Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp</CITATION>

<ORGANIZATION start="24246" party1_of="8194_339" end="24276" id="8194_342" >Walker Process Equipment, Inc.</ORGANIZATION>

<ORGANIZATION start="24246" end="24275" id="8194_352" >Walker Process Equipment, Inc</ORGANIZATION>

<ORGANIZATION start="24280" party2_of="8194_339" end="24310" id="8194_343" >Food Machinery &amp; Chemical Corp</ORGANIZATION>

<CITATION entry_type="standard_key" line="40" id1="Dummy_File_345075" start="24313" lookup_key="u.s._382_172" standard_reporter="U.S." end="24331" page_number="172" reporter="U. S." citation_local_level_id="50" paragraph_number="174" id="8194_337" volume="382" no_current_file="True" citation_global_level_id="345074.003" >382 U. S. 172, 174</CITATION>

<DATE start="24333" citation_local_level_id="50" citation_global_level_id="345074.003" end="24337" id="8194_345" >1965</DATE>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<NAME id="8194_353" start="24402" all_names="SHERMANACT" local_name_id="36" end="24413" >Sherman Act</NAME>

<ORGANIZATION start="24564" end="24569" id="8194_354" >Court</ORGANIZATION>

<ORGANIZATION start="24607" end="24612" id="8194_355" >Court</ORGANIZATION>

<PROFESSION start="25043" document_level_name_id="39" party="ROBERTS" end="25056" id="8194_356" >Chief Justice</PROFESSION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<ORGANIZATION start="25148" end="25153" id="8194_382" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364553" start="25265" line="41" party2_short="Mfg" end="25292" citation_local_level_id="51" party1="United States" citation_global_level_id="364552.001" id="8194_370" no_current_file="True" party2="Singer Mfg" party1_short="States" >United States v. Singer Mfg</CITATION>

<GPE start="25265" party1_of="8194_370" end="25278" id="8194_373" >United States</GPE>

<NAME all_names="SINGERMFG" id="8194_374" start="25282" party2_of="8194_370" local_name_id="39" end="25292" >Singer Mfg</NAME>

<CITATION entry_type="standard_key" line="41" page_number="174" start="25299" lookup_key="u.s._374_174" standard_reporter="U.S." end="25319" year="1963" reporter="U. S." citation_local_level_id="52" citation_global_level_id="364533.003" id="8194_367" id1="Dummy_File_364534" volume="374" no_current_file="True" >374 U. S. 174 (1963)</CITATION>

<DATE start="25314" citation_local_level_id="52" citation_global_level_id="364533.003" end="25318" id="8194_379" >1963</DATE>

<ORGANIZATION start="25400" end="25413" id="8194_383" >third company</ORGANIZATION>

<ORGANIZATION start="25762" end="25767" id="8194_384" >Court</ORGANIZATION>

<NAME id="8194_385" start="25942" all_names="SHERMANACT" local_name_id="36" end="25953" >Sherman Act</NAME>

<PERSON start="26401" end="26406" id="8194_386" >White</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364554" start="26434" line="41" party2_short="Wrinkle" end="26462" citation_local_level_id="53" party1="United States" citation_global_level_id="364553.001" id="8194_371" no_current_file="True" party2="New Wrinkle" party1_short="States" >United States v. New Wrinkle</CITATION>

<GPE start="26434" party1_of="8194_371" end="26447" id="8194_375" >United States</GPE>

<NAME all_names="NEWWRINKLE" id="8194_376" start="26451" party2_of="8194_371" local_name_id="40" end="26462" >New Wrinkle</NAME>

<ORGANIZATION start="26464" end="26467" id="8194_387" >Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364535" start="26470" lookup_key="u.s._342_371" standard_reporter="U.S." end="26488" page_number="371" reporter="U. S." citation_local_level_id="54" paragraph_number="378" id="8194_368" volume="342" no_current_file="True" citation_global_level_id="364534.003" >342 U. S. 371, 378</CITATION>

<DATE start="26490" citation_local_level_id="54" citation_global_level_id="364534.003" end="26494" id="8194_380" >1952</DATE>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364536" start="26548" alternative_keys="['u.s._283_163']" line="41" party2_short="States" end="26591" citation_local_level_id="55" party1="Standard Oil Co. (Indiana)" party2="United States" id="8194_372" citation_global_level_id="364535.004" party1_short="Oil" >Standard Oil Co. (Indiana) v. United States</CITATION>

<NAME id="8194_377" start="26548" all_names="STANDARDOILCO(INDIANA)" local_name_id="11" end="26574" party1_of="8194_372" >Standard Oil Co. (Indiana)</NAME>

<ORGANIZATION start="26548" end="26563" id="8194_388" >Standard Oil Co</ORGANIZATION>

<GPE start="26578" party2_of="8194_372" end="26591" id="8194_378" >United States</GPE>

<CITATION entry_type="standard_key" line="41" id1="Dummy_File_364536" start="26593" lookup_key="u.s._283_163" standard_reporter="U.S." end="26606" page_number="163" reporter="U. S." citation_local_level_id="56" citation_global_level_id="364535.003" id="8194_369" volume="283" no_current_file="True" >283 U. S. 163</CITATION>

<DATE start="26608" citation_local_level_id="56" citation_global_level_id="364535.003" end="26612" id="8194_381" >1931</DATE>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<ORGANIZATION start="26686" end="26691" id="8194_406" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_357215" start="26859" alternative_keys="['u.s._272_476']" line="42" party2_short="Elec" end="26892" citation_local_level_id="57" party1="United States" party2="General Elec. Co" id="8194_402" citation_global_level_id="357214.004" party1_short="States" >United States v. General Elec. Co</CITATION>

<GPE start="26859" party1_of="8194_402" end="26872" id="8194_403" >United States</GPE>

<ORGANIZATION start="26876" party2_of="8194_402" end="26892" id="8194_404" >General Elec. Co</ORGANIZATION>

<PROFESSION start="26876" document_level_name_id="41" party="ELECTRIC" end="26883" id="8194_407" >General</PROFESSION>

<CITATION entry_type="standard_key" page_number="476" start="26895" alternative_keys="['simpsonelec#1']" line="42" standard_reporter="U.S." end="26920" year="1926" lookup_key="u.s._272_476" reporter="U. S." citation_local_level_id="58" paragraph_number="489" id="8194_399" id1="Dummy_File_357215" volume="272" no_current_file="True" citation_global_level_id="357214.003" >272 U. S. 476, 489 (1926)</CITATION>

<DATE start="26915" citation_local_level_id="58" citation_global_level_id="357214.003" end="26919" id="8194_405" >1926</DATE>

<ORGANIZATION start="26926" end="26931" id="8194_408" >Court</ORGANIZATION>

<NAME id="8194_409" start="27054" all_names="LINEMATERIAL" local_name_id="38" end="27067" >Line Material</NAME>

<ORGANIZATION start="27097" end="27102" id="8194_410" >Court</ORGANIZATION>

<ORGANIZATION start="27337" end="27342" id="8194_411" >Court</ORGANIZATION>

<PROFESSION start="27412" document_level_name_id="41" party="ELECTRIC" end="27419" id="8194_412" >General</PROFESSION>

<NAME id="8194_413" start="27420" all_names="ELECTRIC" local_name_id="41" end="27428" >Electric</NAME>

<CITATION entry_type="standard_key" line="42" id1="Dummy_File_364555" start="27525" lookup_key="u.s._333_312" standard_reporter="U.S." end="27542" page_number="312" reporter="U. S." citation_local_level_id="59" citation_global_level_id="364554.001" id="8194_400" volume="333" no_current_file="True" >333 U. S., at 312</CITATION>

<NAME id="8194_414" start="27624" all_names="SHERMANACT" local_name_id="36" end="27635" >Sherman Act</NAME>

<NAME id="8194_415" start="27783" all_names="NEWWRINKLE" local_name_id="40" end="27794" >New Wrinkle</NAME>

<CITATION entry_type="standard_key" line="42" id1="Dummy_File_364556" start="27796" lookup_key="u.s._342_378" standard_reporter="U.S." end="27813" page_number="378" reporter="U. S." citation_local_level_id="60" citation_global_level_id="364555.001" id="8194_401" volume="342" no_current_file="True" >342 U. S., at 378</CITATION>

<ORGANIZATION start="27819" end="27824" id="8194_416" >Court</ORGANIZATION>

<ORGANIZATION start="28133" end="28138" id="8194_417" >Court</ORGANIZATION>

<NAME id="8194_418" start="28221" all_names="SHERMANACT" local_name_id="36" end="28232" >Sherman Act</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<ORGANIZATION start="28259" end="28274" id="8194_425" >Standard Oil Co</ORGANIZATION>

<GPE start="28277" end="28284" id="8194_426" >Indiana</GPE>

<ORGANIZATION start="28291" end="28296" id="8194_427" >Court</ORGANIZATION>

<CITATION entry_type="standard_key" line="43" id1="Dummy_File_364557" start="28400" lookup_key="u.s._283_168" standard_reporter="U.S." end="28417" page_number="168" reporter="U. S." citation_local_level_id="61" citation_global_level_id="364556.001" id="8194_424" volume="283" no_current_file="True" >283 U. S., at 168</CITATION>

<PROFESSION start="28591" document_level_name_id="42" party="BREYER" end="28598" id="8194_428" >Justice</PROFESSION>

<PERSON start="28599" end="28607" id="8194_429" >Brandeis</PERSON>

<ORGANIZATION start="28625" end="28630" id="8194_430" >Court</ORGANIZATION>

<NAME id="8194_431" start="28688" all_names="SHERMANACT" local_name_id="36" end="28699" >Sherman Act</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_347316" start="30105" alternative_keys="['u.s._395_653']" line="44" party2_short="Adkins" end="30125" citation_local_level_id="62" party1="Lear, Inc." party2="Adkins" id="8194_438" citation_global_level_id="347315.004" party1_short="Lear" >Lear, Inc. v. Adkins</CITATION>

<ORGANIZATION start="30105" party1_of="8194_438" end="30115" id="8194_441" >Lear, Inc.</ORGANIZATION>

<ORGANIZATION start="30105" end="30114" id="8194_452" >Lear, Inc</ORGANIZATION>

<PERSON start="30119" party2_of="8194_438" end="30125" id="8194_442" >Adkins</PERSON>

<CITATION entry_type="standard_key" page_number="653" start="30127" line="44" standard_reporter="U.S." end="30152" year="1969" lookup_key="u.s._395_653" reporter="U. S." citation_local_level_id="63" paragraph_number="670" id="8194_435" id1="Dummy_File_347316" volume="395" no_current_file="True" citation_global_level_id="347315.003" >395 U. S. 653, 670 (1969)</CITATION>

<DATE start="30147" citation_local_level_id="63" citation_global_level_id="347315.003" end="30151" id="8194_447" >1969</DATE>

<ORGANIZATION start="30217" end="30222" id="8194_453" >Court</ORGANIZATION>

<ORGANIZATION start="30297" end="30304" id="8194_454" >Company</ORGANIZATION>

<ORGANIZATION start="30312" end="30319" id="8194_455" >Company</ORGANIZATION>

<LEGAL_ROLE start="30419" end="30428" id="8194_456" >defendant</LEGAL_ROLE>

<LEGAL_ROLE start="30444" end="30453" id="8194_457" >plaintiff</LEGAL_ROLE>

<NAME id="8194_458" start="30550" all_names="SCHILDKRAUT" local_name_id="42" end="30561" >Schildkraut</NAME>

<NAME id="8194_459" start="30563" all_names="PATENT-SPLITTINGSETTLEMENTS" local_name_id="43" end="30591" >Patent-Splitting Settlements</NAME>

<NAME id="8194_460" start="30608" all_names="PAYMENTFALLACY" local_name_id="44" end="30623" >Payment Fallacy</NAME>

<NAME id="8194_461" start="30628" all_names="ANTITRUSTLJ" local_name_id="45" end="30642" >Antitrust L. J</NAME>

<DATE start="30656" end="30660" id="8194_448" >2004</DATE>

<LEGAL_ROLE start="30932" end="30941" id="8194_462" >plaintiff</LEGAL_ROLE>

<CITATION lookup_key="b'scounterclaim#1" citation_local_level_id="64" entry_type="case_key" name="B's counterclaim" id="8194_451" start="30977" id1="Dummy_File_364558" no_current_file="True" line="44" citation_global_level_id="364557.001" end="30993" >B's counterclaim</CITATION>

<CITATION entry_type="party_key" line="44" id1="Dummy_File_364559" start="30999" alternative_keys="['f.3d_183_10']" lookup_key="mayerprods#1" party2_short="Prods" end="31050" standard_reporter="F.3D" citation_local_level_id="65" volume="183" party1="Metro-Goldwyn Mayer, Inc." party2="Safety Prods., Inc" id="8194_439" no_current_file="True" page_number="10" citation_global_level_id="364558.003" party1_short="Mayer" >Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc</CITATION>

<ORGANIZATION start="30999" party1_of="8194_439" end="31024" id="8194_443" >Metro-Goldwyn Mayer, Inc.</ORGANIZATION>

<ORGANIZATION start="30999" end="31023" id="8194_463" >Metro-Goldwyn Mayer, Inc</ORGANIZATION>

<ORGANIZATION start="31032" party2_of="8194_439" end="31050" id="8194_444" >Safety Prods., Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_364559" start="31053" alternative_keys="['mayerprods#1']" lookup_key="f.3d_183_10" standard_reporter="F.3D" end="31069" page_number="10" reporter="F. 3d" citation_local_level_id="66" paragraph_number="13" id="8194_436" volume="183" no_current_file="True" citation_global_level_id="364558.003" >183 F. 3d 10, 13</CITATION>

<GPE start="31071" end="31073" id="8194_464" >CA</GPE>

<DATE start="31075" end="31079" id="8194_449" >1999</DATE>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<LEGAL_ROLE start="31435" end="31444" id="8194_465" >plaintiff</LEGAL_ROLE>

<LEGAL_ROLE start="31460" end="31469" id="8194_466" >defendant</LEGAL_ROLE>

<LEGAL_ROLE start="31939" end="31948" id="8194_467" >defendant</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_348610" start="32078" alternative_keys="['u.s._540_398']" line="44" party2_short="Offices" end="32146" citation_local_level_id="67" party1="Verizon Communications, Inc." party2="Law Offices of Curtis V. Trinko, LLP" id="8194_440" citation_global_level_id="348609.011" party1_short="Communications" >Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko, LLP</CITATION>

<ORGANIZATION start="32078" party1_of="8194_440" end="32106" id="8194_445" >Verizon Communications, Inc.</ORGANIZATION>

<ORGANIZATION start="32078" end="32105" id="8194_468" >Verizon Communications, Inc</ORGANIZATION>

<ORGANIZATION start="32110" party2_of="8194_440" end="32146" id="8194_446" >Law Offices of Curtis V. Trinko, LLP</ORGANIZATION>

<ORGANIZATION start="32110" plural="True" end="32121" id="8194_469" >Law Offices</ORGANIZATION>

<CITATION entry_type="standard_key" line="44" id1="Dummy_File_348610" start="32148" lookup_key="u.s._540_398" standard_reporter="U.S." end="32166" page_number="398" reporter="U. S." citation_local_level_id="68" paragraph_number="408" id="8194_437" volume="540" no_current_file="True" citation_global_level_id="348609.003" >540 U. S. 398, 408</CITATION>

<DATE start="32168" citation_local_level_id="68" citation_global_level_id="348609.003" end="32172" id="8194_450" >2004</DATE>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<NAME id="8194_486" start="32240" all_names="HATCH-WAXMANACT" local_name_id="3" end="32256" >Hatch-Waxman Act</NAME>

<CITATION lookup_key="circuit'sview#4" citation_local_level_id="69" entry_type="case_key" name="Circuit's view" id="8194_485" start="32326" id1="Dummy_File_364560" no_current_file="True" line="45" citation_global_level_id="364559.001" end="32340" >Circuit's view</CITATION>

<PROFESSION start="32354" end="32361" id="8194_487" >general</PROFESSION>

<NAME id="8194_488" start="32481" all_names="I-A" local_name_id="46" end="32484" >I-A</NAME>

<ORGANIZATION start="32643" end="32661" id="8194_489" >Antitrust Division</ORGANIZATION>

<ORGANIZATION start="32669" end="32679" id="8194_490" >Department</ORGANIZATION>

<PROFESSION start="32683" document_level_name_id="47" party="BREYER" end="32690" id="8194_491" >Justice</PROFESSION>

<NAME id="8194_492" start="32739" all_names="STAT" local_name_id="23" end="32743" >Stat</NAME>

<NAME id="8194_493" start="32850" all_names="MEMBERS" local_name_id="47" end="32857" >Members</NAME>

<PERSON start="32861" end="32869" id="8194_494" >Congress</PERSON>

<DATE start="32927" end="32931" id="8194_481" >2003</DATE>

<PERSON start="32959" end="32963" id="8194_495" >Cong</PERSON>

<NAME id="8194_496" start="32965" all_names="REC" local_name_id="48" end="32968" >Rec</NAME>

<DATE start="32977" end="32981" id="8194_482" >2002</DATE>

<PERSON start="32995" end="32998" id="8194_497" >Sen</PERSON>

<NAME id="8194_498" start="33044" all_names="HATCH-WAXMANACT" local_name_id="3" end="33060" >Hatch-Waxman Act</NAME>

<PERSON start="33158" end="33162" id="8194_499" >Cong</PERSON>

<NAME id="8194_500" start="33164" all_names="REC" local_name_id="48" end="33167" >Rec</NAME>

<DATE start="33169" end="33173" id="8194_483" >1877</DATE>

<DATE start="33176" end="33180" id="8194_484" >2000</DATE>

<PROFESSION start="33194" document_level_name_id="49" party="REPWAXMAN" end="33197" id="8194_501" >Rep</PROFESSION>

<PERSON start="33194" end="33205" id="8194_502" >Rep. Waxman</PERSON>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<PROFESSION start="33481" end="33488" id="8194_513" >general</PROFESSION>

<CITATION entry_type="standard_key" line="47" id1="Dummy_File_364561" start="33539" lookup_key="f.3d_677_1313" standard_reporter="F.3D" end="33557" page_number="1313" reporter="F. 3d" citation_local_level_id="70" citation_global_level_id="364560.001" id="8194_505" volume="677" no_current_file="True" >677 F. 3d, at 1313</CITATION>

<CITATION entry_type="party_key" line="47" id1="Dummy_File_364562" start="33573" alternative_keys="['f.3d_402_1056']" lookup_key="ploughftc#1" party2_short="FTC" end="33601" standard_reporter="F.3D" citation_local_level_id="71" volume="402" party1="Schering-Plough Corp." party2="FTC" id="8194_508" no_current_file="True" page_number="1056" citation_global_level_id="364561.003" party1_short="Plough" >Schering-Plough Corp. v. FTC</CITATION>

<ORGANIZATION start="33573" party1_of="8194_508" end="33594" id="8194_509" >Schering-Plough Corp.</ORGANIZATION>

<ORGANIZATION start="33573" end="33593" id="8194_514" >Schering-Plough Corp</ORGANIZATION>

<ORGANIZATION start="33598" party2_of="8194_508" end="33601" id="8194_510" >FTC</ORGANIZATION>

<CITATION entry_type="standard_key" line="47" id1="Dummy_File_364562" start="33603" alternative_keys="['ploughftc#1']" lookup_key="f.3d_402_1056" standard_reporter="F.3D" end="33628" page_number="1056" reporter="F. 3d" citation_local_level_id="72" paragraph_number="1074-1075" id="8194_506" volume="402" no_current_file="True" citation_global_level_id="364561.003" >402 F. 3d 1056, 1074-1075</CITATION>

<DATE start="33630" citation_local_level_id="72" citation_global_level_id="364561.003" end="33634" id="8194_511" >2005</DATE>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<CITATION entry_type="case_key" line="47" id1="Dummy_File_364563" start="33644" alternative_keys="['f.3d_466_202']" lookup_key="inretamoxifencitrate#1" standard_reporter="F.3D" end="33667" page_number="202" volume="466" citation_local_level_id="73" citation_global_level_id="364562.003" name="In re Tamoxifen Citrate" id="8194_512" no_current_file="True" >In re Tamoxifen Citrate</CITATION>

<CITATION entry_type="standard_key" line="47" id1="Dummy_File_364563" start="33669" alternative_keys="['inretamoxifencitrate#1']" lookup_key="f.3d_466_202" standard_reporter="F.3D" end="33686" page_number="202" reporter="F. 3d" citation_local_level_id="74" citation_global_level_id="364562.003" name="In re Tamoxifen Citrate" id="8194_507" volume="466" no_current_file="True" >466 F. 3d, at 202</CITATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<ORGANIZATION start="34636" end="34654" id="8194_522" >Indiana Federation</ORGANIZATION>

<CITATION entry_type="standard_key" line="49" id1="Dummy_File_325596" start="34668" lookup_key="u.s._476_460" standard_reporter="U.S." end="34685" page_number="460" reporter="U. S." citation_local_level_id="75" citation_global_level_id="325595.001" id="8194_520" volume="476" no_current_file="True" >476 U. S., at 460</CITATION>

<NAME id="8194_523" start="34700" all_names="AREEDA" local_name_id="19" end="34706" >Areeda</NAME>

<DATE start="34722" end="34726" id="8194_521" >1986</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<PERSON start="36186" end="36194" id="8194_524" >Hemphill</PERSON>

<NAME id="8194_525" start="36249" all_names="LAW" local_name_id="18" end="36252" >Law</NAME>

<PROFESSION start="36269" plural="True" end="36288" id="8194_526" >Business Professors</PROFESSION>

<NAME id="8194_527" start="36299" all_names="AMICICURIAE" local_name_id="49" end="36311" >Amici Curiae</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<NAME id="8194_531" start="37072" all_names="HATCH-WAXMAN" local_name_id="26" end="37084" >Hatch-Waxman</NAME>

<NAME id="8194_532" start="37161" all_names="HATCH-WAXMAN" local_name_id="26" end="37173" >Hatch-Waxman</NAME>

<NAME id="8194_533" start="37324" all_names="I-A" local_name_id="46" end="37327" >I-A</NAME>

<PERSON start="37444" end="37452" id="8194_534" >Hemphill</PERSON>

<LEGAL_ROLE start="37480" end="37490" id="8194_535" >Petitioner</LEGAL_ROLE>

<NAME id="8194_536" start="37494" all_names="SUBSEQUENT" local_name_id="50" end="37504" >Subsequent</NAME>

<PERSON start="38689" end="38697" id="8194_537" >Hemphill</PERSON>

<NAME id="8194_538" start="38980" all_names="HOVENKAMP" local_name_id="20" end="38989" >Hovenkamp</NAME>

<PERSON start="39004" end="39010" id="8194_539" >Lemley</PERSON>

<NAME id="8194_540" start="39074" all_names="SUPP" local_name_id="28" end="39078" >Supp</NAME>

<DATE start="39080" end="39084" id="8194_528" >2011</DATE>

<NAME id="8194_541" start="39107" all_names="HATCH-WAXMAN" local_name_id="26" end="39119" >Hatch-Waxman</NAME>

<NAME id="8194_542" start="39469" all_names="AREEDA" local_name_id="19" end="39475" >Areeda</NAME>

<DATE start="39477" end="39481" id="8194_529" >2046</DATE>

<DATE start="39498" end="39502" id="8194_530" >2010</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<DATE start="39733" end="39737" id="8194_548" >2010</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345279" start="39740" alternative_keys="['u.s._526_756']" line="52" party2_short="FTC" end="39770" citation_local_level_id="76" party1="California Dental Assn." party2="FTC" id="8194_545" citation_global_level_id="345278.005" party1_short="Dental" >California Dental Assn. v. FTC</CITATION>

<ORGANIZATION start="39740" party1_of="8194_545" end="39763" id="8194_546" >California Dental Assn.</ORGANIZATION>

<ORGANIZATION start="39767" party2_of="8194_545" end="39770" id="8194_547" >FTC</ORGANIZATION>

<CITATION entry_type="standard_key" line="52" id1="Dummy_File_345279" start="39772" alternative_keys="['dentalftc#1']" lookup_key="u.s._526_756" standard_reporter="U.S." end="39795" page_number="756" reporter="U. S." citation_local_level_id="77" paragraph_number="786-787" id="8194_544" volume="526" no_current_file="True" citation_global_level_id="345278.003" >526 U. S., 756, 786-787</CITATION>

<DATE start="39797" citation_local_level_id="77" citation_global_level_id="345278.003" end="39801" id="8194_549" >1999</DATE>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<PERSON start="39804" end="39810" id="8194_552" >Breyer</PERSON>

<LEGAL_ROLE start="39944" end="39954" id="8194_553" >Petitioner</LEGAL_ROLE>

<CITATION lookup_key="ftc'scomplaint#3" citation_local_level_id="78" entry_type="case_key" name="FTC's complaint" id="8194_551" start="40817" id1="Dummy_File_364564" no_current_file="True" line="52" citation_global_level_id="364563.001" end="40832" >FTC's complaint</CITATION>

<LEGAL_ROLE start="40847" end="40856" id="8194_554" >defendant</LEGAL_ROLE>

<ORGANIZATION start="41070" end="41088" id="8194_555" >Indiana Federation</ORGANIZATION>

<NAME id="8194_556" start="41119" all_names="AREEDA" local_name_id="19" end="41125" >Areeda</NAME>

<DATE start="41160" end="41164" id="8194_550" >2010</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<DATE start="41569" end="41573" id="8194_561" >2046</DATE>

<ORGANIZATION start="41772" end="41782" id="8194_562" >Commission</ORGANIZATION>

<LEGAL_ROLE start="41968" end="41978" id="8194_563" >Petitioner</LEGAL_ROLE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<FAMILY start="42244" end="42248" id="8194_566" >baby</FAMILY>

<CITATION entry_type="standard_key" line="54" id1="Dummy_File_364543" start="42504" lookup_key="f.3d_677_1312" standard_reporter="F.3D" end="42522" page_number="1312" reporter="F. 3d" citation_local_level_id="79" citation_global_level_id="364542.001" id="8194_564" volume="677" no_current_file="True" >677 F. 3d, at 1312</CITATION>

<NAME id="8194_567" start="43508" all_names="AREEDA" local_name_id="19" end="43514" >Areeda</NAME>

<DATE start="43516" end="43520" id="8194_565" >2046</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<NAME id="8194_571" start="45315" all_names="CALIFORNIADENTAL" local_name_id="51" end="45332" >California Dental</NAME>

<CITATION entry_type="standard_key" line="58" id1="Dummy_File_364565" start="45334" lookup_key="u.s._526_775" standard_reporter="U.S." end="45351" page_number="775" reporter="U. S." citation_local_level_id="80" citation_global_level_id="364564.001" id="8194_568" volume="526" no_current_file="True" >526 U. S., at 775</CITATION>

<LEGAL_ROLE start="45405" end="45414" id="8194_572" >defendant</LEGAL_ROLE>

<NAME id="8194_573" start="45484" all_names="AREEDA" local_name_id="19" end="45490" >Areeda</NAME>

<DATE start="45517" end="45521" id="8194_570" >2010</DATE>

<NAME id="8194_574" start="45548" all_names="CALIFORNIADENTAL" local_name_id="51" end="45565" >California Dental</NAME>

<CITATION entry_type="standard_key" line="58" id1="Dummy_File_364566" start="45892" lookup_key="u.s._526_770" standard_reporter="U.S." end="45909" page_number="770" reporter="U. S." citation_local_level_id="81" citation_global_level_id="364565.001" id="8194_569" volume="526" no_current_file="True" >526 U. S., at 770</CITATION>

<PERSON start="45924" end="45930" id="8194_575" >Breyer</PERSON>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<ORGANIZATION start="46695" end="46705" id="8194_577" >Commission</ORGANIZATION>

<NAME id="8194_578" start="47110" all_names="CALIFORNIADENTAL" local_name_id="51" end="47127" >California Dental</NAME>

<NAME id="8194_579" start="47168" all_names="AREEDA" local_name_id="19" end="47174" >Areeda</NAME>

<DATE start="47190" end="47194" id="8194_576" >1986</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<NAME id="8194_580" start="47772" all_names="CIRCUIT" local_name_id="52" end="47779" >Circuit</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<PROFESSION start="47877" document_level_name_id="53" party="BREYER" end="47884" id="8194_581" >Justice</PROFESSION>

<NAME id="8194_582" start="47885" all_names="ALITO" local_name_id="13" end="47890" >Alito</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<PERSON start="47951" end="47958" id="8194_584" >Roberts</PERSON>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<CITATION entry_type="standard_key" line="65" page_number="____" start="47979" lookup_key="u.s._570_____" standard_reporter="U.S." end="48000" year="2013" reporter="U. S." citation_local_level_id="82" citation_global_level_id="364507.001" id="8194_585" id1="Dummy_File_364508" volume="570" no_current_file="True" >570 U. S. ____ (2013)</CITATION>

<DATE start="47995" citation_local_level_id="82" citation_global_level_id="364507.001" end="47999" id="8194_586" >2013</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<DOCKET lookup_key="commissionactavis#1" citation_local_level_id="15" entry_type="docket" id="8194_588" start="48005" citation_global_level_id="364537.001" no_current_file="True" line="66" id1="Dummy_File_364538" end="48011" >12-416</DOCKET>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364508" start="48012" alternative_keys="['u.s._570_____']" line="67" party2_short="ACTAVIS" end="48072" citation_local_level_id="83" party1="FEDERAL TRADE COMMISSION," party2="ACTAVIS, INC., et al" id="8194_589" party1_role="petitioner" citation_global_level_id="364507.004" party1_short="COMMISSION" >FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al</CITATION>

<NAME id="8194_590" start="48012" all_names="FEDERALTRADECOMMISSION" local_name_id="17" end="48037" party1_of="8194_589" >FEDERAL TRADE COMMISSION,</NAME>

<ORGANIZATION start="48012" end="48036" id="8194_593" >FEDERAL TRADE COMMISSION</ORGANIZATION>

<LEGAL_ROLE start="48038" end="48048" id="8194_592" >PETITIONER</LEGAL_ROLE>

<GPE start="48052" party2_of="8194_589" end="48072" id="8194_591" >ACTAVIS, INC., et al</GPE>

<ORGANIZATION start="48052" end="48064" id="8194_594" >ACTAVIS, INC</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<DATE start="48160" end="48173" id="8194_599" >June 17, 2013</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<PROFESSION start="48176" document_level_name_id="53" party="ROBERTS" end="48189" id="8194_600" >Chief Justice</PROFESSION>

<PERSON start="48190" end="48197" id="8194_601" >Roberts</PERSON>

<PROFESSION start="48209" document_level_name_id="53" party="BREYER" end="48216" id="8194_602" >Justice</PROFESSION>

<PERSON start="48217" end="48223" id="8194_603" >Scalia</PERSON>

<PROFESSION start="48228" document_level_name_id="53" party="BREYER" end="48235" id="8194_604" >Justice</PROFESSION>

<NAME id="8194_605" start="48236" all_names="THOMAS" local_name_id="53" end="48242" >Thomas</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<NAME id="8194_610" start="48262" all_names="SOLVAYPHARMACEUTICALS" local_name_id="4" end="48284" >Solvay Pharmaceuticals</NAME>

<NAME id="8194_611" start="48578" all_names="SOLVAY" local_name_id="7" end="48584" >Solvay</NAME>

<CITATION lookup_key="solvay'spatent#1" citation_local_level_id="84" entry_type="case_key" name="Solvay's patent" id="8194_609" start="48828" id1="Dummy_File_364567" no_current_file="True" line="71" citation_global_level_id="364566.001" end="48843" >Solvay's patent</CITATION>

<ORGANIZATION start="48849" end="48873" id="8194_612" >Federal Trade Commission</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<NAME id="8194_613" start="49127" all_names="SOLVAY" local_name_id="7" end="49133" >Solvay</NAME>

<ORGANIZATION start="49193" end="49198" id="8194_614" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_344509" start="49781" alternative_keys="['u.s._448_176']" line="74" party2_short="Haas" end="49818" citation_local_level_id="85" party1="Dawson Chemical Co." party2="Rohm &amp; Haas Co" id="8194_616" citation_global_level_id="344508.005" party1_short="Chemical" >Dawson Chemical Co. v. Rohm &amp; Haas Co</CITATION>

<ORGANIZATION start="49781" party1_of="8194_616" end="49800" id="8194_617" >Dawson Chemical Co.</ORGANIZATION>

<ORGANIZATION start="49781" end="49799" id="8194_620" >Dawson Chemical Co</ORGANIZATION>

<ORGANIZATION start="49804" party2_of="8194_616" end="49818" id="8194_618" >Rohm &amp; Haas Co</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="176" start="49821" line="74" standard_reporter="U.S." end="49846" year="1980" lookup_key="u.s._448_176" reporter="U. S." citation_local_level_id="86" paragraph_number="215" id="8194_615" id1="Dummy_File_344509" volume="448" no_current_file="True" citation_global_level_id="344508.003" >448 U. S. 176, 215 (1980)</CITATION>

<DATE start="49841" citation_local_level_id="86" citation_global_level_id="344508.003" end="49845" id="8194_619" >1980</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_345075" start="50147" alternative_keys="['u.s._382_172']" line="75" party2_short="Chemical" end="50211" citation_local_level_id="87" party1="Walker Process Equipment, Inc." party2="Food Machinery &amp; Chemical Corp" id="8194_633" citation_global_level_id="345074.005" party1_short="Equipment" >Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp</CITATION>

<ORGANIZATION start="50147" party1_of="8194_633" end="50177" id="8194_637" >Walker Process Equipment, Inc.</ORGANIZATION>

<ORGANIZATION start="50147" end="50176" id="8194_649" >Walker Process Equipment, Inc</ORGANIZATION>

<ORGANIZATION start="50181" party2_of="8194_633" end="50211" id="8194_638" >Food Machinery &amp; Chemical Corp</ORGANIZATION>

<CITATION entry_type="standard_key" line="75" id1="Dummy_File_345075" start="50214" lookup_key="u.s._382_172" standard_reporter="U.S." end="50232" page_number="172" reporter="U. S." citation_local_level_id="88" paragraph_number="177" id="8194_629" volume="382" no_current_file="True" citation_global_level_id="345074.003" >382 U. S. 172, 177</CITATION>

<DATE start="50234" citation_local_level_id="88" citation_global_level_id="345074.003" end="50238" id="8194_645" >1965</DATE>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<PERSON start="50282" end="50294" id="8194_650" >general rule</PERSON>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364533" start="50319" alternative_keys="['u.s._333_287']" line="75" party2_short="Material" end="50352" citation_local_level_id="89" party1="United States" party2="Line Material Co" id="8194_634" citation_global_level_id="364532.005" party1_short="States" >United States v. Line Material Co</CITATION>

<GPE start="50319" party1_of="8194_634" end="50332" id="8194_639" >United States</GPE>

<ORGANIZATION start="50336" party2_of="8194_634" end="50352" id="8194_640" >Line Material Co</ORGANIZATION>

<CITATION entry_type="standard_key" line="75" id1="Dummy_File_364533" start="50355" lookup_key="u.s._333_287" standard_reporter="U.S." end="50373" page_number="287" reporter="U. S." citation_local_level_id="90" paragraph_number="300" id="8194_630" volume="333" no_current_file="True" citation_global_level_id="364532.003" >333 U. S. 287, 300</CITATION>

<DATE start="50375" citation_local_level_id="90" citation_global_level_id="364532.003" end="50379" id="8194_646" >1948</DATE>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364568" start="50523" line="75" party2_short="Elec" end="50552" citation_local_level_id="91" party1="United States" citation_global_level_id="364567.001" id="8194_635" no_current_file="True" party2="General Elec" party1_short="States" >United States v. General Elec</CITATION>

<GPE start="50523" party1_of="8194_635" end="50536" id="8194_641" >United States</GPE>

<NAME all_names="GENERALELEC" id="8194_642" start="50540" party2_of="8194_635" local_name_id="54" end="50552" >General Elec</NAME>

<PROFESSION start="50540" document_level_name_id="41" party="ELECTRIC" end="50547" id="8194_651" >General</PROFESSION>

<CITATION entry_type="standard_key" line="75" id1="Dummy_File_357215" start="50559" alternative_keys="['simpsonelec#1']" lookup_key="u.s._272_476" standard_reporter="U.S." end="50577" page_number="476" reporter="U. S." citation_local_level_id="92" paragraph_number="485" id="8194_631" volume="272" no_current_file="True" citation_global_level_id="357214.003" >272 U. S. 476, 485</CITATION>

<DATE start="50579" citation_local_level_id="92" citation_global_level_id="357214.003" end="50583" id="8194_647" >1926</DATE>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<NAME id="8194_652" start="50711" all_names="SHERMANACT" local_name_id="36" end="50722" >Sherman Act</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_349877" start="50725" alternative_keys="['u.s._377_13']" line="75" party2_short="Oil" end="50756" citation_local_level_id="93" party1="Simpson" party2="Union Oil Co. of Cal" id="8194_636" citation_global_level_id="349876.004" party1_short="Simpson" >Simpson v. Union Oil Co. of Cal</CITATION>

<PERSON start="50725" party1_of="8194_636" end="50732" id="8194_643" >Simpson</PERSON>

<ORGANIZATION start="50736" party2_of="8194_636" end="50756" id="8194_644" >Union Oil Co. of Cal</ORGANIZATION>

<ORGANIZATION start="50736" end="50741" id="8194_653" >Union</ORGANIZATION>

<CITATION entry_type="standard_key" line="75" id1="Dummy_File_349877" start="50759" lookup_key="u.s._377_13" standard_reporter="U.S." end="50775" page_number="13" reporter="U. S." citation_local_level_id="94" paragraph_number="24" id="8194_632" volume="377" no_current_file="True" citation_global_level_id="349876.003" >377 U. S. 13, 24</CITATION>

<DATE start="50777" citation_local_level_id="94" citation_global_level_id="349876.003" end="50781" id="8194_648" >1964</DATE>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<PROFESSION start="51046" document_level_name_id="41" party="ELECTRIC" end="51053" id="8194_654" >General</PROFESSION>

<NAME id="8194_655" start="51054" all_names="ELEC" local_name_id="55" end="51058" >Elec</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364536" start="51320" alternative_keys="['u.s._283_163']" line="76" party2_short="States" end="51363" citation_local_level_id="95" party1="Standard Oil Co. (Indiana)" party2="United States" id="8194_674" citation_global_level_id="364535.005" party1_short="Oil" >Standard Oil Co. (Indiana) v. United States</CITATION>

<NAME id="8194_675" start="51320" all_names="STANDARDOILCO(INDIANA)" local_name_id="11" end="51346" party1_of="8194_674" >Standard Oil Co. (Indiana)</NAME>

<ORGANIZATION start="51320" end="51335" id="8194_679" >Standard Oil Co</ORGANIZATION>

<GPE start="51350" party2_of="8194_674" end="51363" id="8194_676" >United States</GPE>

<CITATION entry_type="standard_key" line="76" id1="Dummy_File_364536" start="51365" lookup_key="u.s._283_163" standard_reporter="U.S." end="51383" page_number="163" reporter="U. S." citation_local_level_id="96" paragraph_number="171" id="8194_673" volume="283" no_current_file="True" citation_global_level_id="364535.003" >283 U. S. 163, 171</CITATION>

<DATE start="51385" citation_local_level_id="96" citation_global_level_id="364535.003" end="51389" id="8194_677" >1931</DATE>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<NAME id="8194_680" start="51546" all_names="SHERMAN" local_name_id="56" end="51553" >Sherman</NAME>

<NAME id="8194_681" start="51890" all_names="JANIS" local_name_id="57" end="51895" >Janis</NAME>

<NAME id="8194_682" start="51913" all_names="LESLIE" local_name_id="58" end="51919" >Leslie</NAME>

<PERSON start="51921" end="51923" id="8194_683" >IP</PERSON>

<DATE start="51969" end="51973" id="8194_678" >2003</DATE>

<NAME id="8194_684" start="51988" all_names="HOVENKAMP" local_name_id="20" end="51997" >Hovenkamp</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364569" start="52279" line="77" party2_short="Mfg" end="52306" citation_local_level_id="97" party1="United States" citation_global_level_id="364568.001" id="8194_691" no_current_file="True" party2="Singer Mfg" party1_short="States" >United States v. Singer Mfg</CITATION>

<GPE start="52279" party1_of="8194_691" end="52292" id="8194_693" >United States</GPE>

<NAME all_names="SINGERMFG" id="8194_694" start="52296" party2_of="8194_691" local_name_id="39" end="52306" >Singer Mfg</NAME>

<CITATION entry_type="standard_key" page_number="174" start="52313" line="77" standard_reporter="U.S." end="52342" year="1963" lookup_key="u.s._374_174" reporter="U. S." citation_local_level_id="98" paragraph_number="196-197" id="8194_689" id1="Dummy_File_364534" volume="374" no_current_file="True" citation_global_level_id="364533.003" >374 U. S. 174, 196-197 (1963)</CITATION>

<DATE start="52337" citation_local_level_id="98" citation_global_level_id="364533.003" end="52341" id="8194_697" >1963</DATE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_335918" start="52540" alternative_keys="['u.s._508_49']" line="77" party2_short="Industries" end="52617" citation_local_level_id="99" party1="Professional Real Estate Investors, Inc." party2="Columbia Pictures Industries, Inc" id="8194_692" citation_global_level_id="335917.008" party1_short="Investors" >Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc</CITATION>

<ORGANIZATION start="52540" party1_of="8194_692" end="52580" id="8194_695" >Professional Real Estate Investors, Inc.</ORGANIZATION>

<ORGANIZATION start="52540" end="52579" id="8194_699" >Professional Real Estate Investors, Inc</ORGANIZATION>

<ORGANIZATION start="52584" party2_of="8194_692" end="52617" id="8194_696" >Columbia Pictures Industries, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="49" start="52620" alternative_keys="['investorsindustries#1']" line="77" standard_reporter="U.S." end="52646" year="1993" lookup_key="u.s._508_49" reporter="U. S." citation_local_level_id="100" paragraph_number="60-61" id="8194_690" id1="Dummy_File_335918" volume="508" no_current_file="True" citation_global_level_id="335917.003" >508 U. S. 49, 60-61 (1993)</CITATION>

<DATE start="52641" citation_local_level_id="100" citation_global_level_id="335917.003" end="52645" id="8194_698" >1993</DATE>

<ORGANIZATION start="52735" end="52751" id="8194_700" >Trademark Office</ORGANIZATION>

<NAME id="8194_701" start="52753" all_names="WALKERPROCESSEQUIPMENT" local_name_id="59" end="52777" >Walker Process Equipment</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<NAME id="8194_709" start="52862" all_names="SOLVAY" local_name_id="7" end="52868" >Solvay</NAME>

<NAME id="8194_710" start="53020" all_names="SOLVAY" local_name_id="7" end="53026" >Solvay</NAME>

<NAME id="8194_711" start="53097" all_names="SOLVAY" local_name_id="7" end="53103" >Solvay</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<ORGANIZATION start="53400" end="53405" id="8194_712" >Court</ORGANIZATION>

<NAME id="8194_713" start="53457" all_names="SOLVAY" local_name_id="7" end="53463" >Solvay</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<ORGANIZATION start="53948" end="53953" id="8194_714" >Court</ORGANIZATION>

<ORGANIZATION start="54207" end="54212" id="8194_715" >Court</ORGANIZATION>

<ORGANIZATION start="54759" end="54764" id="8194_716" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<ORGANIZATION start="55101" end="55106" id="8194_718" >Court</ORGANIZATION>

<NAME id="8194_719" start="55114" all_names="LINEMATERIAL" local_name_id="38" end="55127" >Line Material</NAME>

<ORGANIZATION start="55254" end="55259" id="8194_720" >Court</ORGANIZATION>

<NAME id="8194_721" start="55263" all_names="LINEMATERIAL" local_name_id="38" end="55276" >Line Material</NAME>

<NAME id="8194_722" start="55459" all_names="SHERMANACT" local_name_id="36" end="55470" >Sherman Act</NAME>

<CITATION entry_type="standard_key" line="82" id1="Dummy_File_364570" start="55514" lookup_key="u.s._333_308" standard_reporter="U.S." end="55531" page_number="308" reporter="U. S." citation_local_level_id="101" citation_global_level_id="364569.001" id="8194_717" volume="333" no_current_file="True" >333 U. S., at 308</CITATION>

<NAME id="8194_723" start="55704" all_names="SHERMANACT" local_name_id="36" end="55715" >Sherman Act</NAME>

<ORGANIZATION start="55891" end="55896" id="8194_724" >Court</ORGANIZATION>

<ORGANIZATION start="56105" end="56110" id="8194_725" >Court</ORGANIZATION>

<NAME id="8194_726" start="56502" all_names="SHERMANACT" local_name_id="36" end="56513" >Sherman Act</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<PROFESSION start="57085" end="57095" id="8194_727" >Government</PROFESSION>

<PROFESSION start="57484" end="57494" id="8194_728" >Government</PROFESSION>

<PERSON start="57509" end="57517" id="8194_729" >Congress</PERSON>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<ORGANIZATION start="57573" end="57578" id="8194_735" >Court</ORGANIZATION>

<CITATION entry_type="party_key" line="84" id1="Dummy_File_364535" start="57749" alternative_keys="['u.s._342_371']" lookup_key="manufacturingwrinkle#1" party2_short="Wrinkle" end="57808" citation_local_level_id="102" party1="Singer Manufacturing Co., United States" party2="New Wrinkle, Inc" id="8194_731" citation_global_level_id="364534.004" party1_short="Manufacturing" >Singer Manufacturing Co., United States v. New Wrinkle, Inc</CITATION>

<GPE start="57749" party1_of="8194_731" end="57788" id="8194_732" >Singer Manufacturing Co., United States</GPE>

<ORGANIZATION start="57749" end="57772" id="8194_736" >Singer Manufacturing Co</ORGANIZATION>

<ORGANIZATION start="57792" party2_of="8194_731" end="57808" id="8194_733" >New Wrinkle, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="84" page_number="371" start="57811" alternative_keys="['manufacturingwrinkle#1']" lookup_key="u.s._342_371" standard_reporter="U.S." end="57831" year="1952" reporter="U. S." citation_local_level_id="103" citation_global_level_id="364534.003" id="8194_730" id1="Dummy_File_364535" volume="342" no_current_file="True" >342 U. S. 371 (1952)</CITATION>

<DATE start="57826" citation_local_level_id="103" citation_global_level_id="364534.003" end="57830" id="8194_734" >1952</DATE>

<ORGANIZATION start="57837" end="57852" id="8194_737" >Standard Oil Co</ORGANIZATION>

<GPE start="57855" end="57862" id="8194_738" >Indiana</GPE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<PERSON start="58103" end="58109" id="8194_746" >Singer</PERSON>

<PERSON start="58128" end="58134" id="8194_747" >Singer</PERSON>

<CITATION entry_type="standard_key" line="85" id1="Dummy_File_364571" start="58337" lookup_key="u.s._374_194" standard_reporter="U.S." end="58354" page_number="194" reporter="U. S." citation_local_level_id="104" citation_global_level_id="364570.001" id="8194_743" volume="374" no_current_file="True" >374 U. S., at 194</CITATION>

<NAME id="8194_748" start="58468" all_names="STATES" local_name_id="16" end="58474" >States</NAME>

<ORGANIZATION start="58528" end="58533" id="8194_749" >Court</ORGANIZATION>

<PERSON start="58537" end="58543" id="8194_750" >Singer</PERSON>

<PERSON start="58735" end="58741" id="8194_751" >Singer</PERSON>

<PERSON start="59014" end="59020" id="8194_752" >Singer</PERSON>

<CITATION entry_type="standard_key" line="85" id1="Dummy_File_364572" start="59022" lookup_key="u.s._374_199" standard_reporter="U.S." end="59039" page_number="199" reporter="U. S." citation_local_level_id="105" citation_global_level_id="364571.001" id="8194_744" volume="374" no_current_file="True" >374 U. S., at 199</CITATION>

<PERSON start="59041" end="59046" id="8194_753" >White</PERSON>

<PERSON start="59086" end="59092" id="8194_754" >Singer</PERSON>

<NAME id="8194_755" start="59372" all_names="SHERMANACT" local_name_id="36" end="59383" >Sherman Act</NAME>

<NAME id="8194_756" start="59557" all_names="HOVENKAMP" local_name_id="20" end="59566" >Hovenkamp</NAME>

<PERSON start="59596" end="59602" id="8194_757" >Singer</PERSON>

<PROFESSION start="59846" document_level_name_id="60" party="BREYER" end="59853" id="8194_758" >Justice</PROFESSION>

<PERSON start="59854" end="59859" id="8194_759" >White</PERSON>

<PERSON start="59945" end="59951" id="8194_760" >Singer</PERSON>

<CITATION entry_type="standard_key" line="85" id1="Dummy_File_364573" start="60099" lookup_key="u.s._374_197" standard_reporter="U.S." end="60116" page_number="197" reporter="U. S." citation_local_level_id="106" citation_global_level_id="364572.001" id="8194_745" volume="374" no_current_file="True" >374 U. S., at 197</CITATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<NAME id="8194_769" start="60124" all_names="NEWWRINKLE" local_name_id="40" end="60135" >New Wrinkle</NAME>

<ORGANIZATION start="60170" end="60175" id="8194_770" >Court</ORGANIZATION>

<NAME id="8194_771" start="60449" all_names="SHERMANACT" local_name_id="36" end="60460" >Sherman Act</NAME>

<CITATION entry_type="standard_key" line="86" id1="Dummy_File_364574" start="60463" lookup_key="u.s._342_379" standard_reporter="U.S." end="60480" page_number="379" reporter="U. S." citation_local_level_id="107" citation_global_level_id="364573.001" id="8194_763" volume="342" no_current_file="True" >342 U. S., at 379</CITATION>

<ORGANIZATION start="60511" end="60516" id="8194_772" >Court</ORGANIZATION>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_326180" start="60928" alternative_keys="['u.s._333_364']" line="86" party2_short="Gypsum" end="60968" citation_local_level_id="108" party1="United States" party2="United States Gypsum Co" id="8194_765" citation_global_level_id="326179.008" party1_short="States" >United States v. United States Gypsum Co</CITATION>

<GPE start="60928" party1_of="8194_765" end="60941" id="8194_766" >United States</GPE>

<ORGANIZATION start="60945" party2_of="8194_765" end="60968" id="8194_767" >United States Gypsum Co</ORGANIZATION>

<ORGANIZATION start="60952" end="60968" id="8194_773" >States Gypsum Co</ORGANIZATION>

<CITATION entry_type="standard_key" page_number="364" start="60971" line="86" standard_reporter="U.S." end="60996" year="1948" lookup_key="u.s._333_364" reporter="U. S." citation_local_level_id="109" paragraph_number="400" id="8194_764" id1="Dummy_File_326180" volume="333" no_current_file="True" citation_global_level_id="326179.001" >333 U. S. 364, 400 (1948)</CITATION>

<DATE start="60991" citation_local_level_id="109" citation_global_level_id="326179.001" end="60995" id="8194_768" >1948</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<ORGANIZATION start="61168" end="61183" id="8194_779" >Standard Oil Co</ORGANIZATION>

<GPE start="61186" end="61193" id="8194_780" >Indiana</GPE>

<CITATION entry_type="standard_key" line="87" id1="Dummy_File_364575" start="61372" lookup_key="u.s._283_175" standard_reporter="U.S." end="61389" page_number="175" reporter="U. S." citation_local_level_id="110" citation_global_level_id="364574.001" id="8194_778" volume="283" no_current_file="True" >283 U. S., at 175</CITATION>

<ORGANIZATION start="61395" end="61400" id="8194_781" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<NAME id="8194_782" start="62536" all_names="SHERMANACT" local_name_id="36" end="62547" >Sherman Act</NAME>

<NAME id="8194_783" start="62603" all_names="RUBICON" local_name_id="60" end="62610" >Rubicon</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<PROFESSION start="62647" end="62654" id="8194_791" >general</PROFESSION>

<NAME id="8194_792" start="62685" all_names="HATCH-WAXMANACT" local_name_id="3" end="62701" >Hatch-Waxman Act</NAME>

<NAME id="8194_793" start="62717" all_names="HATCH-WAXMAN" local_name_id="26" end="62729" >Hatch-Waxman</NAME>

<ORGANIZATION start="62899" end="62917" id="8194_794" >Antitrust Division</ORGANIZATION>

<ORGANIZATION start="62925" end="62935" id="8194_795" >Department</ORGANIZATION>

<PROFESSION start="62939" document_level_name_id="61" party="BREYER" end="62946" id="8194_796" >Justice</PROFESSION>

<NAME id="8194_797" start="62966" all_names="HATCH-WAXMANACT" local_name_id="3" end="62982" >Hatch-Waxman Act</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_346489" start="63765" alternative_keys="['u.s._480_522']" line="89" party2_short="States" end="63791" citation_local_level_id="111" party1="Rodriguez" party2="United States" id="8194_786" citation_global_level_id="346488.012" party1_short="Rodriguez" >Rodriguez v. United States</CITATION>

<PERSON start="63765" party1_of="8194_786" end="63774" id="8194_787" >Rodriguez</PERSON>

<GPE start="63778" party2_of="8194_786" end="63791" id="8194_788" >United States</GPE>

<CITATION entry_type="standard_key" line="89" id1="Dummy_File_346489" start="63793" lookup_key="u.s._480_522" standard_reporter="U.S." end="63815" page_number="522" reporter="U. S." citation_local_level_id="112" paragraph_number="525-526" id="8194_785" volume="480" no_current_file="True" citation_global_level_id="346488.003" >480 U. S. 522, 525-526</CITATION>

<DATE start="63817" citation_local_level_id="112" citation_global_level_id="346488.003" end="63821" id="8194_789" >1987</DATE>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<ORGANIZATION start="63881" end="63886" id="8194_798" >Court</ORGANIZATION>

<PROFESSION start="63946" end="63953" id="8194_799" >general</PROFESSION>

<PERSON start="64140" end="64148" id="8194_800" >Congress</PERSON>

<ORGANIZATION start="64219" end="64224" id="8194_801" >Court</ORGANIZATION>

<ORGANIZATION start="64255" end="64267" id="8194_802" >Actavis, Inc</ORGANIZATION>

<ORGANIZATION start="64312" end="64317" id="8194_803" >House</ORGANIZATION>

<NAME id="8194_804" start="64321" all_names="SENATE" local_name_id="61" end="64327" >Senate</NAME>

<DATE start="64334" end="64338" id="8194_790" >2006</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<ORGANIZATION start="64437" end="64447" id="8194_809" >Department</ORGANIZATION>

<PROFESSION start="64451" document_level_name_id="62" party="BREYER" end="64458" id="8194_810" >Justice</PROFESSION>

<ORGANIZATION start="64694" end="64712" id="8194_811" >Antitrust Division</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<LEGAL_ROLE start="65369" end="65378" id="8194_818" >plaintiff</LEGAL_ROLE>

<LEGAL_ROLE start="65384" end="65393" id="8194_819" >defendant</LEGAL_ROLE>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_364559" start="65717" alternative_keys="['f.3d_183_10']" line="91" party2_short="Prods" end="65768" citation_local_level_id="113" party1="Metro-Goldwyn Mayer, Inc." party2="Safety Prods., Inc" id="8194_813" citation_global_level_id="364558.004" party1_short="Mayer" >Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc</CITATION>

<ORGANIZATION start="65717" party1_of="8194_813" end="65742" id="8194_814" >Metro-Goldwyn Mayer, Inc.</ORGANIZATION>

<ORGANIZATION start="65717" end="65741" id="8194_820" >Metro-Goldwyn Mayer, Inc</ORGANIZATION>

<ORGANIZATION start="65750" party2_of="8194_813" end="65768" id="8194_815" >Safety Prods., Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="91" id1="Dummy_File_364559" start="65771" alternative_keys="['mayerprods#1']" lookup_key="f.3d_183_10" standard_reporter="F.3D" end="65787" page_number="10" reporter="F. 3d" citation_local_level_id="114" paragraph_number="13" id="8194_812" volume="183" no_current_file="True" citation_global_level_id="364558.003" >183 F. 3d 10, 13</CITATION>

<GPE start="65789" end="65791" id="8194_821" >CA</GPE>

<DATE start="65793" end="65797" id="8194_816" >1999</DATE>

<NAME id="8194_822" start="65809" all_names="SCHILDKRAUT" local_name_id="42" end="65820" >Schildkraut</NAME>

<NAME id="8194_823" start="65822" all_names="PATENT-SPLITTINGSETTLEMENTS" local_name_id="43" end="65850" >Patent-Splitting Settlements</NAME>

<NAME id="8194_824" start="65867" all_names="PAYMENTFALLACY" local_name_id="44" end="65882" >Payment Fallacy</NAME>

<NAME id="8194_825" start="65887" all_names="ANTITRUSTLJ" local_name_id="45" end="65901" >Antitrust L. J</NAME>

<DATE start="65926" end="65930" id="8194_817" >2004</DATE>

<NAME id="8194_826" start="65943" all_names="ACTAVIS" local_name_id="6" end="65950" >Actavis</NAME>

<NAME id="8194_827" start="66118" all_names="HATCH-WAXMAN" local_name_id="26" end="66130" >Hatch-Waxman</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<ORGANIZATION start="67641" end="67646" id="8194_831" >Court</ORGANIZATION>

<ORGANIZATION start="67847" end="67852" id="8194_832" >Court</ORGANIZATION>

<NAME id="8194_833" start="67927" all_names="HATCH-WAXMAN" local_name_id="26" end="67939" >Hatch-Waxman</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<NAME id="8194_838" start="68594" all_names="HOVENKAMP" local_name_id="20" end="68603" >Hovenkamp</NAME>

<NAME id="8194_839" start="68791" all_names="HERMAN" local_name_id="62" end="68797" >Herman</NAME>

<NAME id="8194_840" start="68809" all_names="STAYDILEMMA" local_name_id="63" end="68821" >Stay Dilemma</NAME>

<NAME id="8194_841" start="68833" all_names="BRAND" local_name_id="64" end="68838" >Brand</NAME>

<NAME id="8194_842" start="68843" all_names="GENERICINCENTIVES" local_name_id="65" end="68861" >Generic Incentives</NAME>

<NAME id="8194_843" start="68893" all_names="PHARMACEUTICALPATENTLITIGATION111COLUM" local_name_id="66" end="68936" >Pharmaceutical Patent Litigation, 111 Colum</NAME>

<DATE start="68946" end="68950" id="8194_834" >1788</DATE>

<DATE start="68952" end="68956" id="8194_835" >1795</DATE>

<DATE start="68965" end="68969" id="8194_836" >2011</DATE>

<PERSON start="68994" end="69001" id="8194_844" >Nachman</PERSON>

<NAME id="8194_845" start="69021" all_names="STANLEYEQUITYRESEARCH" local_name_id="67" end="69044" >Stanley Equity Research</NAME>

<DATE start="69097" end="69101" id="8194_837" >2004</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<ORGANIZATION start="69110" end="69115" id="8194_846" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<LEGAL_ROLE start="70538" end="70547" id="8194_847" >defendant</LEGAL_ROLE>

<LEGAL_ROLE start="70926" end="70935" id="8194_848" >defendant</LEGAL_ROLE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<ORGANIZATION start="72032" end="72037" id="8194_849" >Court</ORGANIZATION>

<PROFESSION start="72822" end="72830" id="8194_850" >attorney</PROFESSION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<DATE start="72954" end="72958" id="8194_851" >2005</DATE>

<DATE start="73411" end="73415" id="8194_852" >2006</DATE>

<ORGANIZATION start="73658" end="73671" id="8194_853" >Supreme Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<PROFESSION start="74445" end="74455" id="8194_855" >Government</PROFESSION>

<LEGAL_ROLE start="74653" end="74663" id="8194_856" >Petitioner</LEGAL_ROLE>

<PROFESSION start="74979" document_level_name_id="41" party="ELECTRIC" end="74986" id="8194_857" >General</PROFESSION>

<NAME id="8194_858" start="74987" all_names="ELEC" local_name_id="55" end="74991" >Elec</NAME>

<CITATION entry_type="standard_key" line="104" id1="Dummy_File_66291" start="74998" lookup_key="u.s._272_488" standard_reporter="U.S." end="75015" page_number="488" reporter="U. S." citation_local_level_id="115" citation_global_level_id="66290.001" id="8194_854" volume="272" no_current_file="True" >272 U. S., at 488</CITATION>

<ORGANIZATION start="75103" end="75108" id="8194_859" >Court</ORGANIZATION>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<NAME id="8194_872" start="75443" all_names="SOLVAY" local_name_id="7" end="75449" >Solvay</NAME>

<NAME id="8194_873" start="75493" all_names="SOLVAY" local_name_id="7" end="75499" >Solvay</NAME>

<ORGANIZATION start="75930" end="75955" id="8194_874" >Pacific Bell Telephone Co</ORGANIZATION>

<ORGANIZATION start="75969" end="75988" id="8194_875" >Communications, Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="107" id1="Dummy_File_364576" start="75991" lookup_key="u.s._555_438" standard_reporter="U.S." end="76009" page_number="438" reporter="U. S." citation_local_level_id="116" paragraph_number="452" id="8194_870" volume="555" no_current_file="True" citation_global_level_id="364575.001" >555 U. S. 438, 452</CITATION>

<DATE start="76011" citation_local_level_id="116" citation_global_level_id="364575.001" end="76015" id="8194_871" >2009</DATE>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<NAME id="8194_877" start="76802" all_names="HOVENKAMP" local_name_id="20" end="76811" >Hovenkamp</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<NAME id="8194_882" start="77108" all_names="HATCH-WAXMAN" local_name_id="26" end="77120" >Hatch-Waxman</NAME>

<ORGANIZATION start="77561" end="77575" id="8194_883" >Administration</ORGANIZATION>

<LEGAL_ROLE start="77637" plural="True" end="77653" id="8194_884" >first applicants</LEGAL_ROLE>

<LEGAL_ROLE start="77798" plural="True" end="77814" id="8194_885" >first applicants</LEGAL_ROLE>

<ORGANIZATION start="77887" end="77895" id="8194_886" >Industry</ORGANIZATION>

<NAME id="8194_887" start="77905" all_names="EXCLUSIVITYWHENMULTIPLEANDASARESUBMITTED" local_name_id="68" end="77950" >Exclusivity When Multiple ANDAs Are Submitted</NAME>

<NAME id="8194_888" start="77963" all_names="DAY" local_name_id="69" end="77966" >Day</NAME>

<DATE start="77970" end="77979" id="8194_878" >July 2003</DATE>

<ORGANIZATION start="78031" end="78065" id="8194_889" >Generic Pharmaceutical Association</ORGANIZATION>

<NAME id="8194_890" start="78069" all_names="AMICUSCURIAE" local_name_id="70" end="78082" >Amicus Curiae</NAME>

<DATE start="78215" end="78219" id="8194_879" >2005</DATE>

<DATE start="78300" end="78304" id="8194_880" >2002</DATE>

<DATE start="78309" end="78313" id="8194_881" >2008</DATE>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<NAME id="8194_891" start="78728" all_names="HATCH-WAXMAN" local_name_id="26" end="78740" >Hatch-Waxman</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<NAME id="8194_892" start="79048" all_names="HATCH-WAXMAN" local_name_id="26" end="79060" >Hatch-Waxman</NAME>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="9252" entry_type="comment" line="16" end="9289" id="8194_129" >invalidating agreement not to compete</COMMENT>

<COMMENT start="18395" entry_type="comment" line="32" end="18492" id="8194_252" >Section 5 &quot;encompass[es] ... practices that violate the Sherman Act and the other antitrust laws&quot;</COMMENT>

<COMMENT start="20640" entry_type="comment" line="34" end="20647" id="8194_296" >similar</COMMENT>

<COMMENT start="20731" entry_type="comment" line="34" end="20738" id="8194_297" >similar</COMMENT>

<COMMENT start="20815" entry_type="comment" line="34" end="20849" id="8194_298" >settlements presumptively unlawful</COMMENT>

<COMMENT start="21734" entry_type="comment" line="38" end="21748" id="8194_317" >emphasis added</COMMENT>

<COMMENT start="24053" entry_type="comment" line="40" end="24243" id="8194_333" >courts must &quot;balance the privileges of [the patent holder] and its licensees under the patent grants with the prohibitions of the Sherman Act against combinations and attempts to monopolize&quot;</COMMENT>

<COMMENT start="24340" entry_type="comment" line="40" end="24413" id="8194_334" >&quot;[E]nforcement of a patent procured by fraud&quot; may violate the Sherman Act</COMMENT>

<COMMENT start="26497" entry_type="comment" line="41" end="26545" id="8194_365" >applying antitrust scrutiny to patent settlement</COMMENT>

<COMMENT start="26615" entry_type="comment" line="41" end="26619" id="8194_366" >same</COMMENT>

<COMMENT start="31082" entry_type="comment" line="44" end="31125" id="8194_433" >describing trademark dispute and settlement</COMMENT>

<COMMENT start="32175" entry_type="comment" line="44" end="32223" id="8194_434" >&quot;[C]ollusion&quot; is &quot;the supreme evil of antitrust&quot;</COMMENT>

<COMMENT start="33637" entry_type="comment" line="47" end="33641" id="8194_504" >same</COMMENT>

<COMMENT start="39804" entry_type="comment" line="52" end="39857" id="8194_543" >Breyer, J., concurring in part and dissenting in part</COMMENT>

<COMMENT start="50241" entry_type="comment" line="75" end="50316" id="8194_625" >&quot; 'A patent . . . is an exception to the general rule against monopolies' &quot;</COMMENT>

<COMMENT start="50382" entry_type="comment" line="75" end="50520" id="8194_626" >&quot;[T]he precise terms of the grant define the limits of a patentee's monopoly and the area in which the patentee is freed from competition&quot;</COMMENT>

<COMMENT start="50586" entry_type="comment" line="75" end="50722" id="8194_627" >&quot;It is only when . . . [the patentee] steps out of the scope of his patent rights&quot; that he comes within the operation of the Sherman Act</COMMENT>

<COMMENT start="50784" entry_type="comment" line="75" end="50791" id="8194_628" >similar</COMMENT>

<COMMENT start="51392" entry_type="comment" line="76" end="51559" id="8194_672" >&quot;Where there are legitimately conflicting claims or threatened interferences, a settlement by agreement, rather than litigation, is not precluded by the [Sherman] Act&quot;</COMMENT>

<COMMENT start="63824" entry_type="comment" line="89" end="63834" id="8194_784" >per curiam</COMMENT>

<COMMENT start="76018" entry_type="comment" line="105" end="76096" id="8194_861" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<COMMENT start="76018" entry_type="comment" line="107" end="76096" id="8194_869" >&quot;We have repeatedly emphasized the importance of clear rules in antitrust law&quot;</COMMENT>

<CITATION entry_type="party_key" line="114" id1="Dummy_File_364577" start="80221" alternative_keys="['f.3d_138_1448']" lookup_key="cybortechs#1" party2_short="Techs" end="80251" standard_reporter="F.3D" citation_local_level_id="117" volume="138" party1="Cybor Corp." party2="FAS Techs., Inc" id="8194_912" no_current_file="True" page_number="1448" citation_global_level_id="364576.003" party1_short="Cybor" >Cybor Corp. v. FAS Techs., Inc</CITATION>

<ORGANIZATION start="80221" party1_of="8194_912" end="80232" id="8194_914" >Cybor Corp.</ORGANIZATION>

<ORGANIZATION start="80221" end="80231" id="8194_921" >Cybor Corp</ORGANIZATION>

<ORGANIZATION start="80236" party2_of="8194_912" end="80251" id="8194_915" >FAS Techs., Inc</ORGANIZATION>

<CITATION entry_type="standard_key" line="114" id1="Dummy_File_364577" start="80254" alternative_keys="['cybortechs#1']" lookup_key="f.3d_138_1448" standard_reporter="F.3D" end="80274" page_number="1448" reporter="F. 3d" citation_local_level_id="118" paragraph_number="1476" id="8194_910" volume="138" no_current_file="True" citation_global_level_id="364576.003" >138 F. 3d 1448, 1476</CITATION>

<NAME id="8194_922" start="80282" all_names="CAFED" local_name_id="37" end="80288" >CA Fed</NAME>

<DATE start="80290" end="80294" id="8194_918" >1998</DATE>

<PERSON start="80308" end="80313" id="8194_923" >Rader</PERSON>

<NAME id="8194_924" start="80364" all_names="FEDERALCIRCUIT" local_name_id="71" end="80379" >Federal Circuit</NAME>

<ORGANIZATION start="80493" end="80527" id="8194_925" >Generic Pharmaceutical Association</ORGANIZATION>

<NAME id="8194_926" start="80531" all_names="AMICUSCURIAE" local_name_id="70" end="80544" >Amicus Curiae</NAME>

<DATE start="80558" end="80562" id="8194_919" >2010</DATE>

<NAME id="8194_927" start="81530" all_names="NEGOTIATIONPROFESSIONALS" local_name_id="72" end="81555" >Negotiation Professionals</NAME>

<NAME id="8194_928" start="81559" all_names="AMICICURIAE" local_name_id="49" end="81571" >Amici Curiae</NAME>

<CITATION entry_type="case_X_vs_Y" id1="Dummy_File_353268" start="82147" alternative_keys="['u.s._550_544']" line="114" party2_short="Twombly" end="82177" citation_local_level_id="119" party1="Bell Atlantic Corp." party2="Twombly" id="8194_913" citation_global_level_id="353267.012" party1_short="Atlantic" >Bell Atlantic Corp. v. Twombly</CITATION>

<ORGANIZATION start="82147" party1_of="8194_913" end="82166" id="8194_916" >Bell Atlantic Corp.</ORGANIZATION>

<ORGANIZATION start="82152" end="82165" id="8194_929" >Atlantic Corp</ORGANIZATION>

<PERSON start="82170" party2_of="8194_913" end="82177" id="8194_917" >Twombly</PERSON>

<CITATION entry_type="standard_key" page_number="544" start="82179" line="114" standard_reporter="U.S." end="82208" year="2007" lookup_key="u.s._550_544" reporter="U. S." citation_local_level_id="120" paragraph_number="558-559" id="8194_911" id1="Dummy_File_353268" volume="550" no_current_file="True" citation_global_level_id="353267.003" >550 U. S. 544, 558-559 (2007)</CITATION>

<DATE start="82203" citation_local_level_id="120" citation_global_level_id="353267.003" end="82207" id="8194_920" >2007</DATE>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Solvay Pharmaceuticals" legal_role="8194_6" id="8194_24" legal_role_string="Respondent" theme="8194_7" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Actavis" legal_role="8194_9" id="8194_25" legal_role_string="respondents" theme="8194_10" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" theme_string="Par" legal_role="8194_21" id="8194_26" legal_role_string="respondent" theme="8194_22" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_34" id="8194_61" standard_case_string="333 U. S. 287, 310" X_vs_Y_string="United States v. Line Material Co" X_vs_Y="8194_38" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_42" party1_string="United States" theme_string="United States v. Line Material Co" id="8194_59" theme="8194_38" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_43" theme_string="United States v. Line Material Co" id="8194_60" theme="8194_38" party2_string="Line Material Co" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_35" id="8194_64" standard_case_string="374 U. S. 174" X_vs_Y_string="United States v. Singer Mfg. Co" X_vs_Y="8194_39" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_44" party1_string="United States" theme_string="United States v. Singer Mfg. Co" id="8194_62" theme="8194_39" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_45" theme_string="United States v. Singer Mfg. Co" id="8194_63" theme="8194_39" party2_string="Singer Mfg. Co" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_36" id="8194_67" standard_case_string="342 U. S. 371" X_vs_Y_string="United States v. New Wrinkle, Inc" X_vs_Y="8194_40" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_46" party1_string="United States" theme_string="United States v. New Wrinkle, Inc" id="8194_65" theme="8194_40" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_47" theme_string="United States v. New Wrinkle, Inc" id="8194_66" theme="8194_40" party2_string="New Wrinkle, Inc" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_37" id="8194_70" standard_case_string="283 U. S. 163" X_vs_Y_string="Standard Oil Co. (Indiana) v. United States" X_vs_Y="8194_41" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_48" party1_string="Standard Oil Co. (Indiana)" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_68" theme="8194_41" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_49" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_69" theme="8194_41" party2_string="United States" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_71" id="8194_81" standard_case_string="476 U. S. 447, 460-461" X_vs_Y_string="FTC v. Indiana Federation of Dentists" X_vs_Y="8194_72" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_73" party1_string="FTC" theme_string="FTC v. Indiana Federation of Dentists" id="8194_79" theme="8194_72" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_74" theme_string="FTC v. Indiana Federation of Dentists" id="8194_80" theme="8194_72" party2_string="Indiana Federation of Dentists" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_82" id="8194_91" standard_case_string="526 U. S. 756, 775" X_vs_Y_string="California Dental Assn. v. FTC" X_vs_Y="8194_83" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_84" party1_string="California Dental Assn." theme_string="California Dental Assn. v. FTC" id="8194_89" theme="8194_83" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_85" theme_string="California Dental Assn. v. FTC" id="8194_90" theme="8194_83" party2_string="FTC" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="570 U. S. ____ (2013)" id="8194_106" at_date_string="2013" theme="8194_104" at_date="8194_105" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_116" party1_string="FEDERAL TRADE COMMISSION," theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_121" theme="8194_115" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_117" theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_122" theme="8194_115" party2_string="ACTAVIS, INC., et al" ></RELATION>

<RELATION gram_type="multi_line" relation_type="asymmetric" includes_docket="8194_114" theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_123" includes_docket_string="12-416" theme="8194_115" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Breyer" id="8194_128" theme="8194_126" profession="8194_125" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_130" id="8194_141" standard_case_string="498 U. S. 46" X_vs_Y_string="Palmer v. BRG of Ga., Inc" X_vs_Y="8194_131" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_132" party1_string="Palmer" theme_string="Palmer v. BRG of Ga., Inc" id="8194_139" theme="8194_131" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_133" theme_string="Palmer v. BRG of Ga., Inc" id="8194_140" theme="8194_131" party2_string="BRG of Ga., Inc" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="498 U. S. 46" id="8194_142" at_date_string="1990" theme="8194_130" at_date="8194_134" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_143" id="8194_151" standard_case_string="677 F. 3d 1298, 1312 (2012)" X_vs_Y_string="FTC v. Watson Pharmaceuticals, Inc" X_vs_Y="8194_144" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_145" party1_string="FTC" theme_string="FTC v. Watson Pharmaceuticals, Inc" id="8194_149" theme="8194_144" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_146" theme_string="FTC v. Watson Pharmaceuticals, Inc" id="8194_150" theme="8194_144" party2_string="Watson Pharmaceuticals, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="677 F. 3d 1298, 1312 (2012)" id="8194_152" at_date_string="2012" theme="8194_143" at_date="8194_147" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_169" id="8194_187" standard_case_string="566 U. S. ___" X_vs_Y_string="Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S" X_vs_Y="8194_171" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_173" party1_string="Caraco Pharmaceutical Laboratories, Ltd." theme_string="Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S" id="8194_185" theme="8194_171" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_174" theme_string="Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S" id="8194_186" theme="8194_171" party2_string="Novo Nordisk A/S" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_170" id="8194_190" standard_case_string="496 U. S. 661, 676 (1990)" X_vs_Y_string="Eli Lilly &amp; Co. v. Medtronic, Inc" X_vs_Y="8194_172" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_175" party1_string="Eli Lilly &amp; Co." theme_string="Eli Lilly &amp; Co. v. Medtronic, Inc" id="8194_188" theme="8194_172" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_176" theme_string="Eli Lilly &amp; Co. v. Medtronic, Inc" id="8194_189" theme="8194_172" party2_string="Medtronic, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="496 U. S. 661, 676 (1990)" id="8194_191" at_date_string="1990" theme="8194_170" at_date="8194_178" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_253" id="8194_278" standard_case_string="476 U. S. 447, 454" X_vs_Y_string="FTC v. Indiana Federation of Dentists" X_vs_Y="8194_255" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_256" party1_string="FTC" theme_string="FTC v. Indiana Federation of Dentists" id="8194_276" theme="8194_255" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_257" theme_string="FTC v. Indiana Federation of Dentists" id="8194_277" theme="8194_255" party2_string="Indiana Federation of Dentists" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="476 U. S. 447, 454" id="8194_279" at_date_string="1986" theme="8194_253" at_date="8194_259" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_281" id="8194_295" standard_case_string="344 F. 3d 1294, 1304" X_vs_Y_string="Valley Drug Co. v. Geneva Pharmaceuticals, Inc" X_vs_Y="8194_284" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_285" party1_string="Valley Drug Co." theme_string="Valley Drug Co. v. Geneva Pharmaceuticals, Inc" id="8194_293" theme="8194_284" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_286" theme_string="Valley Drug Co. v. Geneva Pharmaceuticals, Inc" id="8194_294" theme="8194_284" party2_string="Geneva Pharmaceuticals, Inc" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_299" case_citation_other="8194_306" id="8194_312" standard_case_string="544 F. 3d 1323, 1332-1337" case_citation_other_string="In re Ciprofloxacin Hydrochloride Antitrust Litigation" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_300" case_citation_other="8194_307" id="8194_313" standard_case_string="466 F. 3d 187, 212-213" case_citation_other_string="In re Tamoxifen Citrate Antitrust Litigation" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_301" case_citation_other="8194_308" id="8194_314" standard_case_string="686 F. 3d 197, 214-218" case_citation_other_string="In re K-Dur Antitrust Litigation" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_318" id="8194_329" standard_case_string="333 U. S. 287, 308" X_vs_Y_string="United States v. Line Material Co" X_vs_Y="8194_319" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_320" party1_string="United States" theme_string="United States v. Line Material Co" id="8194_327" theme="8194_319" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_321" theme_string="United States v. Line Material Co" id="8194_328" theme="8194_319" party2_string="Line Material Co" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="333 U. S. 287, 308" id="8194_330" at_date_string="1948" theme="8194_318" at_date="8194_322" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_336" id="8194_359" standard_case_string="333 U. S. 364, 390-391" X_vs_Y_string="United States v. United States Gypsum Co" X_vs_Y="8194_338" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_340" party1_string="United States" theme_string="United States v. United States Gypsum Co" id="8194_357" theme="8194_338" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_341" theme_string="United States v. United States Gypsum Co" id="8194_358" theme="8194_338" party2_string="United States Gypsum Co" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="333 U. S. 364, 390-391" id="8194_360" at_date_string="1948" theme="8194_336" at_date="8194_344" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_337" id="8194_363" standard_case_string="382 U. S. 172, 174" X_vs_Y_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" X_vs_Y="8194_339" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_342" party1_string="Walker Process Equipment, Inc." theme_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" id="8194_361" theme="8194_339" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_343" theme_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" id="8194_362" theme="8194_339" party2_string="Food Machinery &amp; Chemical Corp" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="382 U. S. 172, 174" id="8194_364" at_date_string="1965" theme="8194_337" at_date="8194_345" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_373" party1_string="United States" theme_string="United States v. Singer Mfg" id="8194_389" theme="8194_370" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_374" theme_string="United States v. Singer Mfg" id="8194_390" theme="8194_370" party2_string="Singer Mfg" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="374 U. S. 174 (1963)" id="8194_391" at_date_string="1963" theme="8194_367" at_date="8194_379" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_375" party1_string="United States" theme_string="United States v. New Wrinkle" id="8194_392" theme="8194_371" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_376" theme_string="United States v. New Wrinkle" id="8194_393" theme="8194_371" party2_string="New Wrinkle" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="342 U. S. 371, 378" id="8194_394" at_date_string="1952" theme="8194_368" at_date="8194_380" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_369" id="8194_397" standard_case_string="283 U. S. 163" X_vs_Y_string="Standard Oil Co. (Indiana) v. United States" X_vs_Y="8194_372" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_377" party1_string="Standard Oil Co. (Indiana)" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_395" theme="8194_372" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_378" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_396" theme="8194_372" party2_string="United States" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="283 U. S. 163" id="8194_398" at_date_string="1931" theme="8194_369" at_date="8194_381" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_399" id="8194_421" standard_case_string="272 U. S. 476, 489 (1926)" X_vs_Y_string="United States v. General Elec. Co" X_vs_Y="8194_402" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_403" party1_string="United States" theme_string="United States v. General Elec. Co" id="8194_419" theme="8194_402" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_404" theme_string="United States v. General Elec. Co" id="8194_420" theme="8194_402" party2_string="General Elec. Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="272 U. S. 476, 489 (1926)" id="8194_422" at_date_string="1926" theme="8194_399" at_date="8194_405" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="General" theme_string="Electric" id="8194_423" theme="8194_413" profession="8194_412" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Brandeis" id="8194_432" theme="8194_429" profession="8194_428" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_435" id="8194_472" standard_case_string="395 U. S. 653, 670 (1969)" X_vs_Y_string="Lear, Inc. v. Adkins" X_vs_Y="8194_438" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_441" party1_string="Lear, Inc." theme_string="Lear, Inc. v. Adkins" id="8194_470" theme="8194_438" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_442" theme_string="Lear, Inc. v. Adkins" id="8194_471" theme="8194_438" party2_string="Adkins" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="395 U. S. 653, 670 (1969)" id="8194_473" at_date_string="1969" theme="8194_435" at_date="8194_447" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_436" id="8194_476" standard_case_string="183 F. 3d 10, 13" X_vs_Y_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" X_vs_Y="8194_439" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_443" party1_string="Metro-Goldwyn Mayer, Inc." theme_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" id="8194_474" theme="8194_439" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_444" theme_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" id="8194_475" theme="8194_439" party2_string="Safety Prods., Inc" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_437" id="8194_479" standard_case_string="540 U. S. 398, 408" X_vs_Y_string="Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko, LLP" X_vs_Y="8194_440" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_445" party1_string="Verizon Communications, Inc." theme_string="Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko, LLP" id="8194_477" theme="8194_440" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_446" theme_string="Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko, LLP" id="8194_478" theme="8194_440" party2_string="Law Offices of Curtis V. Trinko, LLP" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="540 U. S. 398, 408" id="8194_480" at_date_string="2004" theme="8194_437" at_date="8194_450" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" profession_string="Rep" theme_string="Rep. Waxman" id="8194_503" theme="8194_502" profession="8194_501" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_506" id="8194_517" standard_case_string="402 F. 3d 1056, 1074-1075" X_vs_Y_string="Schering-Plough Corp. v. FTC" X_vs_Y="8194_508" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_509" party1_string="Schering-Plough Corp." theme_string="Schering-Plough Corp. v. FTC" id="8194_515" theme="8194_508" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_510" theme_string="Schering-Plough Corp. v. FTC" id="8194_516" theme="8194_508" party2_string="FTC" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="402 F. 3d 1056, 1074-1075" id="8194_518" at_date_string="2005" theme="8194_506" at_date="8194_511" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_507" case_citation_other="8194_512" id="8194_519" standard_case_string="466 F. 3d, at 202" case_citation_other_string="In re Tamoxifen Citrate" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_544" id="8194_559" standard_case_string="526 U. S., 756, 786-787" X_vs_Y_string="California Dental Assn. v. FTC" X_vs_Y="8194_545" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_546" party1_string="California Dental Assn." theme_string="California Dental Assn. v. FTC" id="8194_557" theme="8194_545" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_547" theme_string="California Dental Assn. v. FTC" id="8194_558" theme="8194_545" party2_string="FTC" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="526 U. S., 756, 786-787" id="8194_560" at_date_string="1999" theme="8194_544" at_date="8194_549" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Alito" id="8194_583" theme="8194_582" profession="8194_581" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="570 U. S. ____ (2013)" id="8194_587" at_date_string="2013" theme="8194_585" at_date="8194_586" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_590" party1_string="FEDERAL TRADE COMMISSION," theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_595" theme="8194_589" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_591" theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_596" theme="8194_589" party2_string="ACTAVIS, INC., et al" ></RELATION>

<RELATION gram_type="multi_line" relation_type="equivalence" standard_case="8194_585" id="8194_597" standard_case_string="570 U. S. ____ (2013)" X_vs_Y_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" X_vs_Y="8194_589" ></RELATION>

<RELATION gram_type="multi_line" relation_type="asymmetric" includes_docket="8194_588" theme_string="FEDERAL TRADE COMMISSION, PETITIONER v. ACTAVIS, INC., et al" id="8194_598" includes_docket_string="12-416" theme="8194_589" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Chief Justice" theme_string="Roberts" id="8194_606" theme="8194_601" profession="8194_600" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Scalia" id="8194_607" theme="8194_603" profession="8194_602" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="Thomas" id="8194_608" theme="8194_605" profession="8194_604" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_615" id="8194_623" standard_case_string="448 U. S. 176, 215 (1980)" X_vs_Y_string="Dawson Chemical Co. v. Rohm &amp; Haas Co" X_vs_Y="8194_616" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_617" party1_string="Dawson Chemical Co." theme_string="Dawson Chemical Co. v. Rohm &amp; Haas Co" id="8194_621" theme="8194_616" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_618" theme_string="Dawson Chemical Co. v. Rohm &amp; Haas Co" id="8194_622" theme="8194_616" party2_string="Rohm &amp; Haas Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="448 U. S. 176, 215 (1980)" id="8194_624" at_date_string="1980" theme="8194_615" at_date="8194_619" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_629" id="8194_658" standard_case_string="382 U. S. 172, 177" X_vs_Y_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" X_vs_Y="8194_633" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_637" party1_string="Walker Process Equipment, Inc." theme_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" id="8194_656" theme="8194_633" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_638" theme_string="Walker Process Equipment, Inc. v. Food Machinery &amp; Chemical Corp" id="8194_657" theme="8194_633" party2_string="Food Machinery &amp; Chemical Corp" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="382 U. S. 172, 177" id="8194_659" at_date_string="1965" theme="8194_629" at_date="8194_645" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_630" id="8194_662" standard_case_string="333 U. S. 287, 300" X_vs_Y_string="United States v. Line Material Co" X_vs_Y="8194_634" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_639" party1_string="United States" theme_string="United States v. Line Material Co" id="8194_660" theme="8194_634" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_640" theme_string="United States v. Line Material Co" id="8194_661" theme="8194_634" party2_string="Line Material Co" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="333 U. S. 287, 300" id="8194_663" at_date_string="1948" theme="8194_630" at_date="8194_646" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_641" party1_string="United States" theme_string="United States v. General Elec" id="8194_664" theme="8194_635" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_642" theme_string="United States v. General Elec" id="8194_665" theme="8194_635" party2_string="General Elec" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="272 U. S. 476, 485" id="8194_666" at_date_string="1926" theme="8194_631" at_date="8194_647" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_632" id="8194_669" standard_case_string="377 U. S. 13, 24" X_vs_Y_string="Simpson v. Union Oil Co. of Cal" X_vs_Y="8194_636" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_643" party1_string="Simpson" theme_string="Simpson v. Union Oil Co. of Cal" id="8194_667" theme="8194_636" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_644" theme_string="Simpson v. Union Oil Co. of Cal" id="8194_668" theme="8194_636" party2_string="Union Oil Co. of Cal" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="377 U. S. 13, 24" id="8194_670" at_date_string="1964" theme="8194_632" at_date="8194_648" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="General" theme_string="Elec" id="8194_671" theme="8194_655" profession="8194_654" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_673" id="8194_687" standard_case_string="283 U. S. 163, 171" X_vs_Y_string="Standard Oil Co. (Indiana) v. United States" X_vs_Y="8194_674" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_675" party1_string="Standard Oil Co. (Indiana)" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_685" theme="8194_674" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_676" theme_string="Standard Oil Co. (Indiana) v. United States" id="8194_686" theme="8194_674" party2_string="United States" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="283 U. S. 163, 171" id="8194_688" at_date_string="1931" theme="8194_673" at_date="8194_677" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_693" party1_string="United States" theme_string="United States v. Singer Mfg" id="8194_702" theme="8194_691" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_694" theme_string="United States v. Singer Mfg" id="8194_703" theme="8194_691" party2_string="Singer Mfg" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="374 U. S. 174, 196-197 (1963)" id="8194_704" at_date_string="1963" theme="8194_689" at_date="8194_697" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_690" id="8194_707" standard_case_string="508 U. S. 49, 60-61 (1993)" X_vs_Y_string="Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc" X_vs_Y="8194_692" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_695" party1_string="Professional Real Estate Investors, Inc." theme_string="Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc" id="8194_705" theme="8194_692" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_696" theme_string="Professional Real Estate Investors, Inc. v. Columbia Pictures Industries, Inc" id="8194_706" theme="8194_692" party2_string="Columbia Pictures Industries, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="508 U. S. 49, 60-61 (1993)" id="8194_708" at_date_string="1993" theme="8194_690" at_date="8194_698" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_730" id="8194_741" standard_case_string="342 U. S. 371 (1952)" X_vs_Y_string="Singer Manufacturing Co., United States v. New Wrinkle, Inc" X_vs_Y="8194_731" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_732" party1_string="Singer Manufacturing Co., United States" theme_string="Singer Manufacturing Co., United States v. New Wrinkle, Inc" id="8194_739" theme="8194_731" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_733" theme_string="Singer Manufacturing Co., United States v. New Wrinkle, Inc" id="8194_740" theme="8194_731" party2_string="New Wrinkle, Inc" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="342 U. S. 371 (1952)" id="8194_742" at_date_string="1952" theme="8194_730" at_date="8194_734" ></RELATION>

<RELATION gram_type="as_predication" relation_type="asymmetric" profession_string="Justice" theme_string="Singer" id="8194_761" theme="8194_757" profession="8194_758" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="Justice" theme_string="White" id="8194_762" theme="8194_759" profession="8194_758" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_764" id="8194_776" standard_case_string="333 U. S. 364, 400 (1948)" X_vs_Y_string="United States v. United States Gypsum Co" X_vs_Y="8194_765" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_766" party1_string="United States" theme_string="United States v. United States Gypsum Co" id="8194_774" theme="8194_765" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_767" theme_string="United States v. United States Gypsum Co" id="8194_775" theme="8194_765" party2_string="United States Gypsum Co" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="333 U. S. 364, 400 (1948)" id="8194_777" at_date_string="1948" theme="8194_764" at_date="8194_768" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_785" id="8194_807" standard_case_string="480 U. S. 522, 525-526" X_vs_Y_string="Rodriguez v. United States" X_vs_Y="8194_786" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_787" party1_string="Rodriguez" theme_string="Rodriguez v. United States" id="8194_805" theme="8194_786" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_788" theme_string="Rodriguez v. United States" id="8194_806" theme="8194_786" party2_string="United States" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="480 U. S. 522, 525-526" id="8194_808" at_date_string="1987" theme="8194_785" at_date="8194_789" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_812" id="8194_830" standard_case_string="183 F. 3d 10, 13" X_vs_Y_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" X_vs_Y="8194_813" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_814" party1_string="Metro-Goldwyn Mayer, Inc." theme_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" id="8194_828" theme="8194_813" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_815" theme_string="Metro-Goldwyn Mayer, Inc. v. 007 Safety Prods., Inc" id="8194_829" theme="8194_813" party2_string="Safety Prods., Inc" ></RELATION>

<RELATION gram_type="pre_nom" relation_type="asymmetric" profession_string="General" theme_string="Elec" id="8194_860" theme="8194_858" profession="8194_857" ></RELATION>

<RELATION gram_type="parentheses" relation_type="asymmetric" theme_string="555 U. S. 438, 452" id="8194_876" at_date_string="2009" theme="8194_870" at_date="8194_871" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_910" id="8194_932" standard_case_string="138 F. 3d 1448, 1476" X_vs_Y_string="Cybor Corp. v. FAS Techs., Inc" X_vs_Y="8194_912" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_914" party1_string="Cybor Corp." theme_string="Cybor Corp. v. FAS Techs., Inc" id="8194_930" theme="8194_912" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_915" theme_string="Cybor Corp. v. FAS Techs., Inc" id="8194_931" theme="8194_912" party2_string="FAS Techs., Inc" ></RELATION>

<RELATION gram_type="apposition" relation_type="equivalence" standard_case="8194_911" id="8194_935" standard_case_string="550 U. S. 544, 558-559 (2007)" X_vs_Y_string="Bell Atlantic Corp. v. Twombly" X_vs_Y="8194_913" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party1="8194_916" party1_string="Bell Atlantic Corp." theme_string="Bell Atlantic Corp. v. Twombly" id="8194_933" theme="8194_913" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" party2="8194_917" theme_string="Bell Atlantic Corp. v. Twombly" id="8194_934" theme="8194_913" party2_string="Twombly" ></RELATION>

<RELATION gram_type="infix" relation_type="asymmetric" theme_string="550 U. S. 544, 558-559 (2007)" id="8194_936" at_date_string="2007" theme="8194_911" at_date="8194_920" ></RELATION>

